0001279569-14-000141.txt : 20140206 0001279569-14-000141.hdr.sgml : 20140206 20140206150403 ACCESSION NUMBER: 0001279569-14-000141 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 22 CONFORMED PERIOD OF REPORT: 20140206 FILED AS OF DATE: 20140206 DATE AS OF CHANGE: 20140206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LORUS THERAPEUTICS INC CENTRAL INDEX KEY: 0000882361 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32001 FILM NUMBER: 14579677 BUSINESS ADDRESS: STREET 1: 2 MERIDIAN ROAD STREET 2: . CITY: TORONTO STATE: A6 ZIP: M9W 4Z7 MAIL ADDRESS: STREET 1: 2 MERIDIAN ROAD CITY: TORONTO STATE: A6 ZIP: M9W 4Z7 FORMER COMPANY: FORMER CONFORMED NAME: IMUTEC PHARMA INC DATE OF NAME CHANGE: 19970113 FORMER COMPANY: FORMER CONFORMED NAME: IMUTEC CORP DATE OF NAME CHANGE: 19950726 FORMER COMPANY: FORMER CONFORMED NAME: RML MEDICAL LABORATORIES INC DATE OF NAME CHANGE: 19920921 6-K 1 lorus6k.htm FORM 6-K

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the Month of February, 2014

Commission File Number 1-32001

Lorus Therapeutics Inc.

(Translation of registrant’s name into English)

2 Meridian Road, Toronto, Ontario M9W 4Z7

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨ No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82-_______________.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Lorus Therapeutics Inc.


Date: February 6th, 2014	By:	/s/ “Elizabeth Williams”
		Elizabeth Williams
		Director of Finance and Controller

EXHIBIT INDEX

99.1	News Release Dated January 13, 2014 - Lorus Therapeutics to Present at Biotech Showcase^TM 2014
99.2	News Release Dated January 8, 2014 - Lorus Therapeutics Inc. Announces Exercise in Full of Over-Allotment Option in Connection With Public Offering of Common Shares
99.3	News Release Dated December 10, 2013 - Lorus Therapeutics Completes $7,001,500 Prospectus Offering of Common Shares
99.4	News Release Dated December 5, 2013 - Lorus Therapeutics to Present at Oppenheimer & Co. 24^th Annual Healthcare Conference
99.5	News Release Dated December 4, 2013 - Lorus Therapeutics to File Final Prospectus for Equity Offering and Provides Corporate Update
99.6	News Release Dated December 2, 2013 - Lorus Therapeutics Completes New Executive Management Team
99.7	News Release Dated November 22, 2013 - Lorus Therapeutics Inc. Upsizes Overnight Marketed Financing to Approximately C$7,001,500 of Common Shares
99.8	News Release Dated November 21, 2013 - Lorus Therapeutics Inc. Announces C$5,000,000 Overnight Marketed Financing
99.9	News Release Dated October 29, 2013 - Lorus to Focus LOR-253 Development on AML Based on Genetic Insights into the Causes of Certain Hematologic Cancers
99.10	News Release Dated October 28, 2013 - Lorus Therapeutics Appoints New Chief Executive Officer
99.11	News Release Dated October 23, 2013 - Lorus Therapeutics Postpones Annual Meeting Date
99.12	News Release Dated October 11, 2013 - Lorus Therapeutics Apply to Extend Annual Meeting Date

EX-99.1 2 ex991.htm NEWS RELEASES DATED JANUARY 13, 2014

Exhibit 99.1

Lorus Therapeutics to Present at Biotech Showcase^TM 2014

TORONTO, ONTARIO - January 13, 2014 - Lorus Therapeutics Inc. (TSX: LOR) today announced that William G. Rice, Ph.D., Chairman and Chief Executive Officer, will be presenting at Biotech Showcase 2014 on Wednesday, January 15, 2014, 4:30 pm PST at the Parc 55 Wyndham, San Francisco.

Dr. Rice will provide a corporate overview of the company’s new strategic direction, including plans to develop Lorus’ lead clinical agent LOR-253 for acute myeloid leukemia (AML) and other hematological cancers. Lorus is focusing the development of LOR-253 in specific hematologic malignancies based on recent scientific insights into the underlying genetics of these diseases among certain patient subpopulations.

About Lorus

Lorus is a biopharmaceutical company targeting essential apoptosis pathways to deliver transformational cancer drugs. Lorus’ goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used alone and in combination with other drugs to successfully treat specific forms of cancer. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and US securities laws. Such statements include, but are not limited to, statements relating to: the ability of the Company to continue as a going concern, the ability to find future financing, the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “should”, “would”, “may”, and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such risks and uncertainties could include, among others: our ability to continue to operate as a going concern; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

# # #

Contacts:

Lorus Therapeutics

Grace Tse, 416-798-1200, ext. 380

gtse@lorusthera.com

BCC Partners

Karen L. Bergman or Susan Pietropaolo

650-575-1509 or 845-638-6290

kbergman@bccpartners.com or spietropaolo@bccpartners.com

EX-99.2 3 ex992.htm NEWS RELEASES DATED JANUARY 8, 2014

Exhibit 99.2

LORUS THERAPEUTICS INC. ANNOUNCES EXERCISE IN FULL OF OVER-ALLOTMENT OPTION IN CONNECTION WITH PUBLIC OFFERING OF COMMON SHARES

TORONTO, ONTARIO - January 8, 2014 - Lorus Therapeutics Inc. (TSX:LOR) (“Lorus” or the “Company”) announces that the underwriters have exercised in full their over-allotment option to purchase an additional 1,909,500 common shares of the Company at a price of $0.55 per common share, in connection with the previously announced public offering of common shares of Lorus which was completed on December 10, 2013. As a result of the exercise of this over-allotment option, Lorus received additional gross proceeds of $1,050,225 and will have raised total gross proceeds of $8,051,725 from its public offering. The offering was co-led by a Clarus Securities Inc. and Canaccord Genuity Corp. and included Jennings Capital Inc. and D&D Securities Inc. as well as PowerOne Capital Markets Limited as a member of the selling group.

The securities being offered have not, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from the U.S. registration requirements. This release does not constitute an offer for sale or the solicitation of an offer to buy securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Lorus

Forward Looking Statements

We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Enquiries:

For further information, please contact:

Greg Chow, CFO

416-798-1200

gchow@lorusthera.com

For US media, please contact:

BCC Partners

Karen L. Bergman or Susan Pietropaolo

650-575-1509 or 845-638-6290

kbergman@bccpartners.com or spietropaolo@bccpartners.com

EX-99.3 4 ex993.htm NEWS RELEASES DATED DECEMBER 10, 2013

Exhibit 99.3

Lorus Therapeutics Completes $7,001,500 Prospectus Offering of Common Shares

TORONTO, ONTARIO - December 10, 2013 - Lorus Therapeutics Inc. (TSX: LOR) (“Lorus” or the “Company”) has completed today its previously announced public offering of common shares of the Company (the “Offered Shares”).

The Company issued a total of 12,730,000 Offered Shares at a price of $0.55 per Offered Share (the “Offering Price”), for aggregate gross proceeds of $7,001,500 (the “Offering”). The Offering was sold to a syndicate of underwriters co-led by Clarus Securities Inc. and Canaccord Genuity Corp. and including Jennings Capital Inc. and D&D Securities Inc. (collectively, the “Underwriters”) as well as PowerOne Capital Markets Limited as a member of the selling group, upon the terms of an underwriting agreement entered into among the Company and the Underwriters. In addition, the Company has granted the Underwriters an over-allotment option to purchase that number of additional common shares equal to 15% of the Offered Shares sold pursuant to the Offering at the Offering Price for a period ending 30 days following the closing of the Offering (the “Over-Allotment Option”).

Lumira Capital, Canada’s largest life science venture capital investment manager, has participated in the Offering. Commenting on the investment, Lumira Capital Managing Director Dr. Brian Underdown noted, “We have followed the company for some time but only recently felt that changes in its management, scientific advisors and product development strategy and focus reflected the kind of inflection point needed to move the company forward and to position it for the future. We are excited to be an investor in the company and look forward to working with the management team to help them execute and realize on their new business plan and vision for the company.”

Concurrent with the closing of the financing, Dr. Underdown will join Lorus’ Board of Directors, replacing Mr. Herbert Abramson who will be stepping down effective immediately.

“We are honored to have the support of such a prestigious fund as Lumira and we are delighted to welcome Dr. Underdown to the Lorus Board. He brings an impressive combination of skills with both operational and board experience, as well as significant scientific expertise,” stated Dr. William G. Rice, Chairman and Chief Executive Officer of Lorus. “We would like to thank Mr. Abramson for his relentless and unwavering personal support and considerable contributions as a member of the Board and Audit and Corporate Governance Committees.”

Mr. Sheldon Inwentash, exercising control or direction over more than 10% of the common shares of the Company, participated in the Offering and acquired, both personally and through Pinetree Capital Ltd., an aggregate of 1,820,000 Offered Shares. After the close of the Offering, Mr. Inwentash and his joint actors, collectively hold 7,520,000 common shares of Lorus (12.65% of the issued and outstanding), 5,000,000 common share purchase warrants and convertible promissory notes in the amount of $150,000, convertible, at a conversion price of $0.30 per common share, into a maximum of 500,000 common shares of Lorus. If Mr. Inwentash and his joint actors were to exercise all of the warrants and convert all the convertible promissory notes controlled by them, they would hold 13,020,000 common shares of Lorus (20.05% of the issued and outstanding on a partially diluted basis). The participation of Mr. Inwentash and his joint actors in the Offering constitutes a “related party transaction” as defined under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Offering is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of securities being issued to insiders nor the consideration being paid by insiders will exceed 25% of the Company’s market capitalization. The Company did not file a material change report 21 days prior to the closing of the Offering as the details of the participation of insiders of the Company had not been confirmed at that time.

Lorus intends to use the net proceeds from the offering to fund its clinical trial program, manufacturing program and for general and corporate working capital purposes.

The Offered Shares were distributed under a short form prospectus dated December 5, 2013 and details of the distribution are set out in the short form prospectus which is available on SEDAR at www.sedar.com.

About Lorus

Forward Looking Statements

# # #

Enquiries:

For further information, please contact:

Grace Tse, 416-798-1200, ext. 380

gtse@lorusthera.com

For US media, please contact:

BCC Partners

Karen L. Bergman or Susan Pietropaolo

650-575-1509 or 845-638-6290

kbergman@bccpartners.com or spietropaolo@bccpartners.com

EX-99.4 5 ex994.htm NEWS RELEASES DATED DECEMBER 5, 2013

Exhibit 99.4

Lorus Therapeutics to Present at Oppenheimer & Co. 24^th Annual Healthcare Conference

TORONTO, ONTARIO - December 5, 2013 - Lorus Therapeutics Inc. (TSX: LOR) (“Lorus” or the “Company”) today announced that William G. Rice, Ph.D., Chairman and Chief Executive Officer, will be presenting at the Oppenheimer & Co. 24^th Annual Healthcare Conference on Tuesday, December 10, 2013, 1:35 pm ET at the Crowne Plaza Times Square Manhattan.

About Lorus

Forward Looking Statements

# # #

Contacts:

Lorus Therapeutics

Grace Tse, 416-798-1200, ext. 380

gtse@lorusthera.com

BCC Partners

Karen L. Bergman or Susan Pietropaolo

650-575-1509 or 845-638-6290

kbergman@bccpartners.com or spietropaolo@bccpartners.com

EX-99.5 6 ex995.htm NEWS RELEASES DATED DECEMBER 4, 2013

Exhibit 99.5

Lorus Therapeutics to File Final Prospectus for Equity Offering and Provides Corporate Update

TORONTO, ONTARIO - December 4, 2013 - Lorus Therapeutics Inc. (TSX: LOR) (“Lorus” or the “Company”), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that it expects to file a final prospectus relating to the previously announced public offering of 12,730,000 common shares of the Company (the “Offered Shares”) at a price of $0.55 per Offered Share (the “Offering Price”) for aggregate gross proceeds of $7,001,500 (the “Offering”).

In connection with the Offering, Lorus has entered into an underwriting agreement with a syndicate of underwriters co-led by Clarus Securities Inc. and Canaccord Genuity Corp. and including Jennings Capital Inc. and D&D Securities Inc. (collectively, the “Underwriters”) to sell the Offered Shares. In addition, the Company has granted the Underwriters an over-allotment option to purchase that number of additional common shares equal to 15% of the Offered Shares sold pursuant to the Offering at the Offering Price for a period ending 30 days following the closing of the Offering (the “Over-Allotment Option”).

The Common Shares will be offered in British Columbia, Alberta and Ontario by way of short form prospectus. The short form prospectus will also qualify the distribution of the Offered Shares to be issued pursuant to the Over-Allotment Option.

The net proceeds from the Offering will be used for clinical trial and manufacturing program of the Company and for general corporate purposes. The Offering is expected to close on or about December 10, 2013, subject to customary conditions and all regulatory approvals

The Company also wishes to confirm that, further to the formation in September 2013 of a special committee composed of independent directors to review strategic alternatives available to the Corporation, (the “Special Committee”), the Special Committee, after having considered and reviewed a number of options, concluded its strategic review process on October 28, 2013. As previously announced, on October 28, 2013 the Special Committee recommended that the board of directors of Lorus (the “Board”) approve the appointments of William G. Rice, Ph.D. as Chief Executive Officer and Chairman of the Board and of Daniel D. Von Hoff, M.D., to serve as a special advisor to fulfill the functions of the Corporation’s Senior Vice President of Medical Affairs. The Board, after receiving the recommendation of the Special Committee, unanimously approved the appointments. In doing so, the Board determined that such appointments were in the best interest of Lorus, as they were considered to enhance the management team and advisory team with the addition of two seasoned and experienced biotechnology executives bringing extensive clinical development and capital raising experience and improving the awareness and presence of the Corporation in the United States. Also, as previously announced on December 2, 2013, Avanish Vellanki was appointed as Chief Business Officer of the Corporation and Gregory K. Chow was appointed as its Chief Financial Officer to complete the new executive management team of Lorus.

About Lorus

Forward Looking Statements

Enquiries:

For further information, please contact:

Grace Tse, 416-798-1200, ext. 380

gtse@lorusthera.com

For US media, please contact:

BCC Partners

Karen L. Bergman or Susan Pietropaolo

650-575-1509 or 845-638-6290

kbergman@bccpartners.com or spietropaolo@bccpartners.com

EX-99.6 7 ex996.htm NEWS RELEASES DATED DECEMBER 2, 2013

Exhibit 99.6

Lorus Therapeutics Completes New Executive Management Team

Avanish Vellanki and Gregory K. Chow Join as

Chief Business Officer and Chief Financial Officer

TORONTO, ONTARIO - December 2, 2013 - Lorus Therapeutics Inc. (TSX: LOR) (“Lorus” or the “Company”) today announced the appointment of Avanish Vellanki as Chief Business Officer (CBO) and Gregory K. Chow as Chief Financial Officer (CFO) of the Company. In his role as CBO, Mr. Vellanki will manage global business development, licensing and corporate strategy. Mr. Chow will have global responsibility for corporate finance and accounting functions at Lorus. Both Mr. Vellanki and Mr. Chow will report to William G. Rice, Ph.D., Chairman and Chief Executive Officer of Lorus.

The additions of Mr. Vellanki and Mr. Chow follow the recent announcements of Dr. Rice joining as Chief Executive Officer and Chairman of the Board of Directors and Daniel D. Von Hoff, M.D., serving in a key advisory capacity as Senior Vice President of Medical Affairs.

“Mr. Vellanki and Mr. Chow represent critical additions to the team at this pivotal point in the Company’s transition in leadership and focus,” said Dr. Rice. “Avanish brings considerable experience from the life science and banking industries that will boost our abilities to build and advance our oncology pipeline and identify new markets for Lorus’ platform. Greg brings impressive corporate finance and capital raising experience for life science companies, as well as deep industry relationships essential to establishing a foundation for Lorus’ value and future growth.”

The Company previously announced that it intends to focus development of its lead compound LOR-253 on acute myeloid leukemia (AML) and other hematological cancers based on recent insights into the underlying genetics, disease target and patient population.

“Driven by the potential for LOR-253 to transform treatment of AML, and the other anticancer programs at Lorus, we have been able to attract a stellar team with the oncology clinical development and deep pharmaceutical business expertise to take the Company to the next level,” Dr. Rice continued.

Mr. Vellanki was mostly recently a Senior Vice President in Investment Banking at Wedbush Securities in San Francisco, covering the biotechnology sector. Previously, Mr. Vellanki was a Senior Director of Corporate Development of Proteolix, Inc. (acquired by Onyx Pharmaceuticals), a private biotechnology company based in South San Francisco focused on the development of oncology therapeutics, most notably Kyprolis^® (carfilzomib), for patients with hematologic malignancies and other cancers. He previously served as Vice President in the Global Healthcare Investment Banking team at Citigroup, where he focused on large cap global biopharmaceutical strategic and financing transactions. Mr. Vellanki began his career at Bear Stearns as an equity research analyst covering the small/mid-cap biotechnology sector, and held the title of Vice President as a publishing analyst. He is also a co-founder and Chairman of the Board of Independence Brewing Company Pvt. Ltd., one of the first craft microbreweries in India. Mr. Vellanki holds a BA from Carleton College, an MBS in Biochemistry from the University of Minnesota and MBA from the Carlson School of Management at the University of Minnesota.

Mr. Chow previously held the position of Managing Director, and led the Private Placements team in the Life Sciences Investment Banking Group at Wedbush Securities. Prior to joining Wedbush, he was a Director in the Private Placements / Equity Capital Markets Group at RBC Capital Markets where he led the life science private capital activities. Mr. Chow’s transactional experience covers a broad range of equity and equity-linked financings that include Initial Public Offerings, Follow-Ons, Confidentially Marketed Public Offerings, Registered Directs, Private Investment in Public Equities (PIPEs) and private placements for private companies. Prior to RBC, he directed the Private Capital Group at Wells Fargo Securities, and was a Senior Auditor at BDO Seidman, LLP. Mr. Chow is a Certified Public Accountant (Inactive) in the State of California. Mr. Chow received his MBA in Finance from the Wharton School at the University of Pennsylvania, and his BA in Business Economics with an emphasis in Accounting from the University of California, Santa Barbara.

About Lorus

Forward Looking Statements

# # #

Enquiries:

For further information, please contact:

Grace Tse, 416-798-1200, ext. 380

gtse@lorusthera.com

For US media, please contact:

BCC Partners

Karen L. Bergman or Susan Pietropaolo

650-575-1509 or 845-638-6290

kbergman@bccpartners.com or spietropaolo@bccpartners.com

EX-99.7 8 ex997.htm NEWS RELEASES DATED NOVEMBER 22, 2013

Exhibit 99.7

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

LORUS THERAPEUTICS INC. UPSIZES OVERNIGHT MARKETED FINANCING TO APPROXIMATELY C$7,001,500 OF COMMON SHARES

Toronto, Ontario - Lorus Therapeutics Inc. (TSX:LOR) (“Lorus” or the “Company”) announces that it has upsized the previously announced C$5,000,000 overnight marketed public offering (the “Offering”) to 12,730,000 common shares of the Company (“Common Shares") to be issued at a purchase price of $0.55 per Common Share, for gross proceeds of $7,001,500. The Company has agreed to grant to the Underwriters an over-allotment option to purchase up to that number of additional Common Shares equal to 15% of the Common Shares sold pursuant to the Offering at the offering price for a period ending 30 following the closing of the Offering.

The Common Shares were offered in British Columbia, Alberta and Ontario by short form prospectus. The net proceeds from the Offering will be used for clinical trial and manufacturing program of the Company and for general corporate purposes.

The Offering is expected to close on or about December 11, 2013, subject to customary conditions and all regulatory approvals including the approval of the Toronto Stock Exchange and of applicable securities regulatory authorities.

About Lorus

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and US securities laws. Such statements include, but are not limited to, statements relating to: the ability of the company to continue as a going concern, the ability to find future financing, the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “should”, “would”, “may”, and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such risks and uncertainties could include, among others: our ability to continue to operate as a going concern; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Enquiries:

For further information, please contact:

Elizabeth Williams, 416-798-1200, ext. 372

ewilliams@lorusthera.com

For US media, please contact:

BCC Partners

Karen L. Bergman or Susan Pietropaolo

650-575-1509 or 845-638-6290

kbergman@bccpartners.com or spietropaolo@bccpartners.com

EX-99.8 9 ex998.htm NEWS RELEASES DATED NOVEMBER 21, 2013

Exhibit 99.8

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

LORUS THERAPEUTICS INC. ANNOUNCES C$5,000,000

OVERNIGHT MARKETED FINANCING

Toronto, Ontario - Lorus Therapeutics Inc. (TSX:LOR) (“Lorus” or the “Company”) announces that it has filed and received a receipt for a preliminary short form prospectus in connection with a C$5,000,000 overnight marketed public offering (the “Offering”) of common shares of the Company (the “Common Shares”). The Offering will be conducted through a syndicate of underwriters co-led by Clarus Securities Inc. and Canaccord Genuity Corp. (the “Underwriters”). The Company has agreed to grant to the Underwriters an over-allotment option to purchase that number of additional Common Shares equal to 15% of the Common Shares sold pursuant to the Offering at the offering price for a period ending 30 following the closing of the Offering. The definitive price of the Offering will be determined in the context of the market with the final terms to the agreed at the time of entering into of an underwriting agreement.

The Common Shares will be offered in British Columbia, Alberta and Ontario by short form prospectus. The net proceeds from the Offering will be used for clinical trial and manufacturing program of the Company and for general corporate purposes.

About Lorus

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and US securities laws. Such statements include, but are not limited to, statements relating to: the ability of the company to continue as a going concern, the ability to find future financing, the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “should”, “would”, “may”, and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such risks and uncertainties could include, among others: our ability to continue to operate as a going concern; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled “Risk Factors” in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

Enquiries:

For further information, please contact:

Elizabeth Williams, 416-798-1200, ext. 372

ewilliams@lorusthera.com

For US media, please contact:

BCC Partners

Karen L. Bergman or Susan Pietropaolo

650-575-1509 or 845-638-6290

kbergman@bccpartners.com or spietropaolo@bccpartners.com

EX-99.9 10 ex999.htm NEWS RELEASES DATED OCTOBER 29, 2013

Exhibit 99.9

Lorus to Focus LOR-253 Development on AML Based on Genetic Insights into the Causes of Certain Hematologic Cancers

Silencing of the KLF4 Tumor Suppressor by CDX2 is a Critical Oncogenic Event in AML; LOR-253 Can Reactivate the Silenced KLF4 Gene

Brian Druker, M.D. Appointed Chair of the Newly-Formed Scientific Advisory Board

TORONTO, ONTARIO - October 29, 2013 - Lorus Therapeutics Inc. (TSX: LOR) (Lorus), announced today that the company will pursue the clinical development of LOR-253, its first-in-class, small molecule inducer of the tumor suppressor Krüppel-like factor 4 (KLF4), in acute myeloid leukemia (AML) and other hematologic malignancies.

“AML represents an area of tremendous unmet medical need and intense medical research. Recent research in AML has implicated up-regulation of various transcription factors, including CDX2, as causative in the development or progression of leukemic disease, while absent in the hematopoietic stem and progenitor cells of healthy individuals,” said Dr. William G. Rice, Chairman and CEO of Lorus. “Notably, the CDX2 protein is reported to silence the KLF4 gene as a critical oncogenic event in AML1, and LOR-253 has the potential to reactivate the silenced KLF4 gene and induce apoptosis.”

“These findings present an immense opportunity for LOR-253 in the selection and treatment of patients with suppressed KLF4 in AML, Myelodysplastic Syndromes, and potentially other hematologic malignancies,” said Dr. Rice. “We will continue to evaluate our technologies in promising indications, like AML, that offer the benefit of achieving rapid clinical proof of concept and an expedited regulatory path.”

“Additionally, based upon our new understanding of the role of KLF4 in various cancers, we will explore the potential for targeting subsets of patients with non-small cell lung cancer that may be mechanistically predisposed for response to LOR-253,” added Dr. Rice.

Lorus also announced today the addition of Brian Druker, M.D. as the Chair of the Company’s newly-formed Scientific Advisory Board.

“As evidenced by his instrumental role in the development of Gleevec for patients with chronic myeloid leukemia, Dr. Druker is a leading scientist and thought leader in hematologic malignancies, and we are privileged to have the opportunity to work with him in realizing the potential of Lorus’ anti-cancer therapeutic platform,” said Daniel Von Hoff, M.D., who serves as Lorus’ Senior Vice President of Medical Affairs.

“Patients and their families continue to suffer as a consequence of the mortality and morbidity associated with AML,” commented Dr. Druker. “As a physician committed to the discovery and development of new agents to better treat AML and other blood cancers, I am delighted to work with Bill Rice and Dan Von Hoff in guiding the clinical development of this novel small molecule program for this underserved population.”

“We are very fortunate to have the extraordinary hematology/oncology leadership of Dr. Brian Druker as the Chair of our Scientific Advisory Board,” said Dr. Rice. “We intend to build a world-class SAB, led by Dr. Druker, and expect it to be a major driver of the LOR-253 development strategy in AML and other indications.”

Dr. Druker is director of the Knight Cancer Institute at Oregon Health & Science University, associate dean for oncology in the OHSU School of Medicine, JELD-WEN Chair of Leukemia Research at OHSU, and an investigator of the Howard Hughes Medical Institute. His research helped prove it was possible to shut down cells that enable cancer to grow without also harming healthy cells. This breakthrough, which resulted in the once-a-day cancer pill Gleevec^®, has made once-fatal forms of the disease now manageable. Initially approved to treat chronic myeloid leukemia (CML), Gleevec is now FDA-approved for 10 cancers, and hundreds of other targeted therapies have been developed in its wake.

Dr. Druker has received numerous honors for his groundbreaking work including the 2009 Lasker-Debakey Award for Clinical Research (often referred to as America’s Nobel), the Japan Prize and top awards from the American Cancer Society, the Lance Armstrong Foundation, American Society of Hematology, and the Leukemia and Lymphoma Society, among others. He was elected to the Institute of Medicine of the National Academies in 2003, the American Association of Physicians in 2006, and the National Academy of Sciences in 2007.

About Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia is a rapidly progressing cancer of the blood and bone marrow characterized by the uncontrolled proliferation of dysfunctional myeloblasts that do not mature into healthy blood cells. It is the most common form of acute leukemia in adults, and the American Cancer Society estimates there will be approximately 14,590 new cases of AML and approximately 10,370 deaths from AML in the U.S. in 2013. Standard induction therapy with chemotherapy is successful in many AML patients, but the majority of these patients will relapse with treatment refractory disease. Patients with relapsed or refractory disease and newly diagnosed AML patients over 60 years of age with poor prognostic risk factors typically die within one year, a fact that highlights an acute need for new treatment options.

About LOR-253

LOR-253 represents an entirely new class of anticancer agents, which we believe may offer a competitive advantage over conventional drugs. LOR-253 is a small molecule optimized to induce the tumor suppressor Krüppel-like factor 4 (KLF4), leading to apoptotic death in cancer cells that have the KLF4 gene silenced. This drug candidate has shown selective and potent antitumor activity in preclinical investigations, including in solid and liquid tumors, and has demonstrated a robust safety profile and biological activity in a Phase 1 clinical trial in patients with non-small cell lung cancer.

About Lorus

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: the ability of the company to continue as a going concern, the ability to find future financing, the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “should”, “would”, “may”, and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such risks and uncertainties could include, among others: our ability to continue to operate as a going concern; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

# # #

Enquiries:

For further information, please contact:

Grace Tse, 416-798-1200, ext. 380

ir@lorusthera.com

For US media, please contact:

BCC Partners

Karen L. Bergman or Susan Pietropaolo

650-575-1509 or 845-638-6290

kbergman@bccpartners.com or spietropaolo@bccpartners.com

¹ J Clin Invest. 2013;123(1):299–314. doi:10.1172/JCI64745

EX-99.10 11 ex9910.htm NEWS RELEASES DATED OCTOBER 28, 2013

Exhibit 99.10

NEWS RELEASE

Lorus Therapeutics Appoints New Chief Executive Officer

William G. Rice, Ph.D. Appointed CEO and Chairman of the Board

Daniel D. Von Hoff, M.D., FACP to Serve as Key Advisor

US Biotechnology Industry Veteran Brings Extensive Clinical Development and Capital Raising Experience

TORONTO, ONTARIO - October 28, 2013 - Lorus Therapeutics Inc. (TSX: LOR) (“Lorus” or the “Company), today announced the appointment of William Rice, Ph.D. as its Chief Executive Officer and Chairman of the Board of Directors. Lorus specializes in targeting essential apoptosis pathways to deliver transformational cancer drugs, and Dr. Rice will guide the strategic and clinical missions of the Company.

“Dr. Rice is a biotech veteran with more than 20 years of leadership experience and a successful record of strategic, scientific and financing accomplishments. We are privileged to announce his addition to the Lorus team,” said Jim A. Wright, Ph.D., who will be transitioning from Chairman of the Board to Lead Director. “We also want to thank Dr. Aiping Young for her unwavering service as the former President and Chief Executive Officer,” said Dr. Wright. “Dr. Young will continue to contribute to the cutting-edge research and operational activities as the President and Chief Operating Officer of the Company.”

“The outstanding research team at Lorus has built a staged pharmaceutical pipeline of innovative therapies to address the needs of patients with cancer,” said Dr. Rice. “I look forward to working with the team to expeditiously advance these programs, and the Board has provided the latitude for us to explore all available options to maximize shareholder value.”

Dr. Rice was most recently President, CEO and Chairman of the Board at Cylene Pharmaceuticals, Inc., a clinical-stage private company where he led the strategic and financing activities to design and develop small molecule therapeutics to exploit CK2-driven pathways and non-genotoxic mechanisms for activating p53 to kill cancer cells. Prior to Cylene, Dr. Rice was the Founder, President, Chief Executive Officer and Director of Achillion Pharmaceuticals, Inc., served as Head of the Drug Mechanism Laboratory at the National Cancer Institute-Frederick Cancer Research and Development Center, and served as a faculty member in the division of Pediatric Hematology and Oncology at Emory University School of Medicine.

Lorus also announced today the addition of Daniel D. Von Hoff, M.D. as the Company’s Senior Vice President of Medical Affairs. Dr. Von Hoff is the Physician-in-Chief, Distinguished Professor at Translational Genomics Research Institute in Phoenix, Arizona and Professor of Medicine, Mayo Clinic, Scottsdale, AZ. He and his colleagues led the development of many cancer agents now used routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, irinotecan, nelarabine, capecitabine, lapatinib, vismodegib, nab-paclitaxel and others. Dr. Von Hoff has published more than 629 papers and 137 book chapters, 1066 abstracts, is a founder of ILEX™ Oncology, and is the editor and past editor of multiple cancer publications. He received the 2010 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology (ASCO) and served on President Bush’s National Cancer Advisory Board, as President of the American Association for Cancer Research and on the board of ASCO.

“The portfolio of programs at Lorus has tremendous potential in a variety of oncology indications,” said Dr. Von Hoff. “I am very impressed with the quality of discovery capabilities at Lorus.”

“Dr. Von Hoff’s reputation and capabilities are unrivaled in the oncology community,” stated Dr. Wright. “Dr. Rice and Dr. Von Hoff will provide Lorus with a tremendous infusion of business and clinical expertise.”

The Special Committee of independent directors established by the Board of Directors of Lorus to review strategic alternatives available to the Company (the “Special Committee”), after having considered and reviewed a number of options, has recommended that the Board of Directors of Lorus approve the appointments. The Board of Directors, after receiving the recommendation of the Special Committee, unanimously approved the appointments. In doing so, the Board determined that such appointments are in the best interest of Lorus, as they enhance the management team with the addition of two seasoned and experienced biotechnology executives who bring extensive clinical development and capital raising experience and improve the awareness and presence of the Company in the United States. Dr. Rice, as the new CEO and Chairman of the Board of Directors of Lorus, has been authorized and mandated by the Board to explore all available options to maximize shareholder value.

About Lorus

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Canadian and US securities laws. Such statements include, but are not limited to, statements relating to: the ability of the company to continue as a going concern, the ability to find future financing, the Company’s plans, objectives, expectations and intentions and other statements including words such as “continue”, “expect”, “intend”, “will”, “should”, “would”, “may”, and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such risks and uncertainties could include, among others: our ability to continue to operate as a going concern; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

# # #

Enquiries:

For further information, please contact:

Grace Tse, 416-798-1200, ext. 380

ir@lorusthera.com

For US media, please contact:

BCC Partners

Karen L. Bergman or Susan Pietropaolo

650-575-1509 or 845-638-6290

kbergman@bccpartners.com or spietropaolo@bccpartners.com

EX-99.11 12 ex9911.htm NEWS RELEASES DATED OCTOBER 23, 2013

Exhibit 99.11

NEWS RELEASE

Lorus Therapeutics Postpones Annual Meeting Date

TORONTO, ONTARIO - October 23, 2013 - Lorus Therapeutics Inc. (TSX: LOR) (“Lorus” or the “Company”), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced that following the press release dated October 11, 2013 it has now obtained court approval to delay the date of its 2013 Annual General Meeting to a date which will be no later than March 31, 2014.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics in cancer. Lorus’ goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR.

Forward Looking Statements

Lorus Therapeutics Inc.’s recent press releases are available through its website at www.lorusthera.com. For Lorus' regulatory filings on SEDAR, please go to www.Sedar.com.

For further information, please contact:

Lorus Therapeutics Inc.

Elizabeth Williams, Director of Finance, 1-416-798-1200 ext. 372

ewilliams@lorusthera.com

EX-99.12 13 ex9912.htm NEWS RELEASES DATED OCTOBER 11, 2013

Exhibit 99.12

NEWS RELEASE

Lorus Therapeutics Apply to Extend Annual Meeting Date

TORONTO, ONTARIO - October 11, 2013 - Lorus Therapeutics Inc. (TSX: LOR) (“Lorus” or the “Company”), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, issued a Notice of Application in the Ontario Superior Court of Justice, Commercial List (the “Court”) today. The application seeks an order pursuant to Section 133(b) of the Canada Business Corporations Act (the “CBCA”) extending the time for Lorus to call the next annual meeting of its shareholders (“AGM”) to March 31, 2014, together with an order validating service of the application materials in the manner described in the affidavit of Aiping Young, President and CEO of Lorus, sworn October 10, 2013. The application is scheduled to be heard before a judge of the Court on October 23, 2013, at 10:00 a.m., at 330 University Avenue, Toronto, Ontario.

In support of the application, Lorus will today file with the Court the following materials (the “Court Materials”): Application Record, containing the Notice of Application, the Affidavit of Aiping Young, sworn October 10, 2013 and a draft Order; Factum; and, Brief of Authorities. The Court Materials will be posted on Lorus’ website at www.lorusthera.com.

Lorus had originally intended to hold its Annual General Meeting before November 30, 2013. However, as

Lorus advances in its previously announced strategic review process, management has come to believe that such process may result in the requirement to present one or more matters to shareholders for approval. Therefore, with a view to avoiding an unnecessary duplication of expenses, Lorus is requesting court approval to delay the holding of its Annual General Meeting.

About Lorus

Forward Looking Statements

Lorus Therapeutics Inc.’s recent press releases are available through its website at www.lorusthera.com. For Lorus' regulatory filings on SEDAR, please go to www.Sedar.com.

For further information, please contact:

Lorus Therapeutics Inc.

Elizabeth Williams, Director of Finance, 1-416-798-1200 ext. 372

ewilliams@lorusthera.com

GRAPHIC 14 image_001.gif GRAPHIC begin 644 image_001.gif M1TE&.#EA7@%?`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"'Y M!`$`````+`````!=`5X`AP``````````,P``9@``F0``S```_P`S```S,P`S M9@`SF0`SS``S_P!F``!F,P!F9@!FF0!FS`!F_P"9``"9,P"99@"9F0"9S`"9 M_P#,``#,,P#,9@#,F0#,S`#,_P#_``#_,P#_9@#_F0#_S`#__S,``#,`,S,` M9C,`F3,`S#,`_S,S`#,S,S,S9C,SF3,SS#,S_S-F`#-F,S-F9C-FF3-FS#-F M_S.9`#.9,S.99C.9F3.9S#.9_S/,`#/,,S/,9C/,F3/,S#/,_S/_`#/_,S/_ M9C/_F3/_S#/__V8``&8`,V8`9F8`F68`S&8`_V8S`&8S,V8S9F8SF68SS&8S M_V9F`&9F,V9F9F9FF69FS&9F_V:9`&:9,V:99F:9F6:9S&:9_V;,`&;,,V;, M9F;,F6;,S&;,_V;_`&;_,V;_9F;_F6;_S&;__YD``)D`,YD`9ID`F9D`S)D` M_YDS`)DS,YDS9IDSF9DSS)DS_YEF`)EF,YEF9IEFF9EFS)EF_YF9`)F9,YF9 M9IF9F9F9S)F9_YG,`)G,,YG,9IG,F9G,S)G,_YG_`)G_,YG_9IG_F9G_S)G_ M_\P``,P`,\P`9LP`F/($.*'$FRI,F3*%.J7,FRI<`,+'KSR*]B[8W?@W4%V M[-G'$"`,`DRXLN7+%[TZ94H#+^(RB/,VO7#V`=JIF'^N3&!:K7;^W=CJB]FG=>]Z25K&"VB\>A_K>`#A M`0U!/KTB__7JJBK/1.(3[5P)$ZE4[PD@)*`1_X&.SEZ07TR$M'QYY`#RQ]\@ MXZ&W&D4P$:C>@@&FMYY$`OIGU'GE41717[5Y!U]W--@W'7H4O:9=;HK=ELAM M),JV&V^1_5:3%_?QQMV,,M)`PR`J-4>#C#S2&-F,-$Q'T50-2*%TEJ*6:8,U#D'%I[A6;==%]09QUB M3<%F@6FE<>BB34AQ5Y]\01YUTBS8T.+*#$?.AY]RYR4%IGR%ZM#E@0O!)%!R M.^XYGX;;;9>EI;+IYY"D1]%2::&]>5H13Z/JR5^@"UTED!<=TO_GA1<%)K4= MHP_0"N%CI^6&UQ=EM`DLBF2MN&5Q-B4R99T#7VSK$+9+/N"J1CLFR2Q$1O9VKD&T>,&;#M<^%N=F=EW'YHG7W97= M:=_>B2>I#[0"*DDPP5J?D!>FBR1JU]X:7P+B$B0JAS/J>NVB]>D0;46S?*&A M9!&EVZ=""7;XA42P\=8K;5\H-:QM*>I@`5HL]EBQ3&%R]W%(%_\H<$2)&!GF MNA"UW%W!#27"H[L3R:LD#1U)W=W/")5Q)-4..8=TTY'->1J^G>D`6G7]+D67 M66+7J6=O?MKTFJ4[=\33VV5B[="7;W/_5V9$7]#M4-%]JR51&99^C5$B]56Y M]Z9Z$V04N!$I'79LL]U5F\R>-29GSF-"$#E+4HIN4BLTP]V?ALY2L_9+7+8=^7 M.6-VB=584Y?KT=)F]).>0>!=(`G:U3PB(C$I+B%6\QE$R*6DWKV*1P^TR"!D MU#NCT6N"O9M;=]J&O+UTIFRB<8H*CT>CB>%*8P493MRP$0V3Z,!2(S%*JE;E MD59LBD/@:9K@_Y)FJ:$MA'&%8I8%%8)$[Q@1(><#VI3P=QK9A"4W93D>BV;4 MI`?,0&/>P\8L*)"#+B!BB1AQF`1%LL$?T>!Z%G&:C][8$-RMT7X.C(@=H](^ M%L%Q(%FZHTU%A(IO'JQ8^(`%"`E0@QM"%@R`B!S+H`@X.848T M3J1ZC$I`#F_(H0QN1(W=2408"V*^4/Z1(+^K3_T>$LONF')(-)(=3#;T@$0` MZB._`QW^(@.;LI0E@#_J(A;6T@I$=&$,.*BD01*!@QQ$\YE=Z,(A?BF2=G$' M@;J3$DF"F3N&1)!I$*'=D6YYD`A"@)T2:>,"'=(RWH%$7GLR'IVTR/](Y['P M2`BH$J`0`;4;G"4S`4$48S:YT`6:9O.D`D%$-;')R9Z.X8PA M0>5#&[*[(SVQ(X24T0<5@KO(+%&.Z]1C^OKXHU<&*DR1F<%0$V*R;#WOR71'I`>P)!6UI5\X;-G M.JE5T<&^#R*!P]C5<'J112E)I3ES:2&(TW1[U@!2.R10C_6%6V4>6(/,T%$5=D24JSS`AL M+%4N$N[3-&^C;&M;,0NT.C>M!S6(`ZS)T+=:%Q$QW4A$Y3-7;.#S2*TE"4E3 MJ;5/2G:GM3'$/-"I$@LZ!I9FM* M8)H:1*?71$1H3;M@!3M8KAP1ZCVE5-B,D),[["RJ4Y,FI=M>D$9+C:\?)=)4 M+3FNL>7"%9+F-$(@36P&HB3(,Y]+8TH6Y!ID<"Y<'6S&0.QXJP4!Y<1"TL)W MGH1PC5JE0%HY,:O^#CZQ34@M<]6^7%[(N]OKV_"4W"H#/C9TI4N`F`\4B&QJ M\K/7K"F$"8*#:%+2_[1PCC.#'=3+)=*QZ;41)C M$*DR\O!`-"PFK5I$5/95<:0G]@`$W*D5T,WTFHUR2;2^=+^+!O'F/B1A?2PLG,D*-);%_C/&F40619TE%>"&R\#.8E438! M5RB(0L\\X`%+DR">?::&;4":6RR(L#1`VENIFF,B(/-8KHX:&@@6`'G62""X*SP M\:\,C"??#1)P^VS$+]VQW`"`16@\D2E=L.2L%4^K$6:TSB*>E+/7_\F M=IB.366"C&&S,R:P9M4QSBZ06G`P?4XA)\N5TX[9GLHG9 MK&`E(QB>^]"ZE1'0(41L(T>-8)+&.@(J'<-]I[62J_%"6W=\QK*SHL'6K3/+ M<.B1J_3-X21Y-:XP+JU)8[UQP1[<1[7MNUV[6B#D>CLD>V)!E)?.@%P\]M=: M@=D",SN;!VI%M%].[20MOR(R]'G#\=H$"FGQSC^,LBSF/^JUJ?XB0N0L2 MAS7Y=(&D3^28?%Z$\&U3L=Y/W[Q]1"#Q?2"P^S7_NR.F\AX],@%_Q@::S:S9 M:!Z(#!2H)B5'BW/+\]C&:>31]PL2/B5Q?R*TDR0T,'7@%V@)X5L@=Q'Z=22M MAV(_`DQ/`S<044/J=7>D0EF69A`U5F,Q-0N)0$:>MF-F%%H^9EHC*(*'@&>G M%A).\U'B12I44UZS-DT_!"Y;Y5X-&$>-0X!Q5(,B!8#%YDB4!2FSX'B-9U,$ M@0CQIUG:=((-%F?61E"<1$EXIGD?D7(\B%(]$VSC=D0],GN[@E554TX02&@4 MH3"*E5PTL'6HEF\;6%#/1@N(`'":U%/7=89<5=\!1(A,V__%Q'R]H,5 M9SWFE(:^-!'9,V_?5ST=_Q*(=:181K<0C-8S790`6(`3[+>)SX8-9.``;79F MV"1\]!=7!,5CAP!:V,0*^3=;(+%NP+-_!P&+%>5.LA-[\U0O'<81+`*)#8%T M%-%KOV8IC]1R`/:&S]8*GY@##A!\7#!_>!B-HB5MM[9VA=)YPD,P/-011!$7 M^=0][36#"6%[I@(1108>-31R1X$K@O(1:Y%8?Q6,[Y9XCS0TK6"$9C00E[2$ MDS>*/*5-/P60TSB%V-1S$V&%'^$*WX*-"Q%X+=(UV38NM35^$A%8MK013S:) M%F9B&,%Q&X)^6V=$SJ5)0%5S.$"'S_6,!=F$(@A7U45)/[6'?<.0#&&1\Y-\ M3_\W(SJ0A0-!?139$`Y9'ZR23N*';=R1B7MC:QA4('U7R?5>R(3B"DP0!C_+!DP+Q2^X%-[T3#5.6?:<2/@F0@])"B!/$ M:G.E*#-0,4@A=FUVFZ'8>$>XE3#IC[W9FUN9$:63EHVE.`OH1F7Y.D]XQHI:/D^5R=>"J2]H-`-CD0 M`'H"44.#<&KNTCOGDJ1Z8F8"]GAINIMI:F86ZJ8%IFT!^#!`1A4_HC>9^300,SAJY'2"N"2! M*'>/Y9SW8TOP,PBM8R8T^IZ]_S@3NW>CD(JC-394E(&E0.(;'T(>ZC$(B<"I MTS$=CC(#=S4?D>,53[I7;2)&VQ8O$44#@3DN`Y%4?@=X$4%R'")+R0DKO!0D MZP$J,*%JNAHK74*@"#%L?)(?'Y,40.*+'.&F[<>),(>5:693HOAXCTD+295R M`E1^R51T#[$4VMH;CG)ZL#*/>WHMR#&/Q/0DBG9AO`$M36E]^LDC0;)TX$IA M-^AELJ$4BJ)&YRH3^A:I`HNCE=2-43.,L7(IPWBK#"MX!%-J>^,*,&)W6K:: MC_))OI-E])&PM_J(\P5^8(*P&A(M^,6J%(LKC@(8G><5\I-U6D:(G)D2B+"F M$-ILC_^GFS7[>#]*$:X`(#U!&3_++8("(#E1M$B!%%21M$IK+==R(E)1.OO* MJ30Y*3[+*C]+M,OQ:%@['%;E%78QGUPR"*`9$>4!(ZBTKTQ[$S8JJ6R[@35% MK`@S$+XJMYFQ;7ZR&G!K'.#8$X#"MR=Q%1.RMP,QM1XQ"YLEH3@;*93:C[NK#K$D4(K6GVK*%K9@89N[J[NR*A8`.;DLQ5C;S;$H0[O#YA<(YG MLS95DL;;O,[KCM=@@LXD?*46L\];$@FC`T9ZO=S;O6[X. ML4$E"KF,0[[FV[Y2UDNP"['N.[_7(F4W0K_XB[]&Y#2:FRSY^[\6<0T*J1^K MX315D;3Q6A1(48U'ZQ6J"E_\\3%=X@JN(`C;J>L0T@)38 M`+ZW\P6``CY].!!.%"]#_"C*,J!#S&X;YP4)<&FQ!BA4+&ZN"1N0`BMA*K?8 M(CU\;"YKX0J%YFL3PKY8C!G;,8OP_RL0RG(GOE6O8,);`Y'(0>8%KL*_!4') MDP(!X86@L\(EG?F3(H,LHPPO(2H0PS--=7S(UQLXLVB=L_,=1:$L?M(3YQ(_ M.SFX`Y&.C$/*J&84O;$:X$)XK/+$8>>:KX+,`Y$`P>5##S0A-Z0K_8TLX?-=$L0XRPYV(D4HG0P]$P90FP?6*/'!9C'RBP0'CHIK@J.&5<4 M@:*0'"K/G0L;U[S(OJ/1W-(=E`'.96P5JRPO"*3)&7L@8!)<=R(RJY'.Z(Q. M%E/..Y+/X.`'&/1LT;O+.`0BOPCJ)[#R-;J:M*I#Q\I<-+/Y%7$ GRAPHIC 15 image_001.jpg GRAPHIC begin 644 image_001.jpg M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX. M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_ MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T] M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`##`L\#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH MHH`**CGGBMHFEGD2.->2SG`%Z8?Q?=3\SR?RJHPE+9&-]>MSSY]![U+XBUV#P_I,EW-A MG^[%'GEV[#_&O&KJ_N-4OY+N\D,DTAR3V'H!Z`5T4*/M'=['#C,7[%RN%GM97AF0 M_*Z'!%>E>$?B"FI.EAJY2*[;B.8<)*?0^C?H:\Q>H'I5:49K4,-B)TGIL?1U M%<+\//%[:I#_`&7J$FZ\B7,4C'F5!Z^X_4?C7=5Y>^:\ M^\6^'[WPI>Q*M]/+;3@F*3>5.1U!YZ\BMH4XS=DSFJUITES..GJ>V45\Z_VA M>$8^V7./^NS?XUW'A'P.VN:8FHZG?W:Q2D^7'')@D`XR2<]Q5SPZ@KR9G3QC MJRY8Q_$]1I:QM#\+6/A^262S>Y9I5"MYLQ<8'MTK9KG=KZ'9%MK4****0PHH MHH`****`"BBDH`6DK)UWQ/IOAZ'=?3_O6&4A3EV_#M]37G6J_$O6-3E\C2HA M:(YPH1?,E;\?\!6L*,I[&%7$4Z>C>IZS)(D2%Y'5%'4L<"LV?Q1HEL<3:K9J M1V$H)_2O-+?P-XGU]A-J,C1!N=UY*6;_`+YYQ^E;-O\`"*(*/M.JN3W$4(`_ M4FJ]G3C\4C/VU:7PP^\ZG_A-_#O_`$%K?]?\*L0>*M#N#B+5K,D]C*!_.N6/ MPET\KQJ-V#ZE5_PK/O/A).JDV.IQR'^[-&5_49_E34:+^T)U,2OLH]+BGBN$ MW0RI(OJC`C]*?7A.H>'==\,OYLT,\"`\3P.2O_?2]/QQ5[2OB+KFG%1-,M[$ M/X9QS_WT.?SS3>&;5XNY*QJ3M4C8]IHKF/#_`(]TO766%F-I=MP(I3PQ_P!E MNA_G735A*+B[,[(3C-7B[BT445)044R6,2Q/&V=KJ5.#@X/O7(S_``STJ1#Y M-UJ$+]F$^['X&JBD]V1-R7PJYV-)7A/B+3=0\,ZN]E)>S.NT/'(KL-ZGVSP> M#631?#7Q',`9KV" M,GLT[L?T%/?X7Z\HRFHVS'T\V0?TJ/90_G-O;U/^?;/5J2O&;KPCXMTH%XQ< MR*/XK:X+'\LY_2J5MXR\1:;*5_M&X+(<&.X&_'L0W-4L/S?#),AXWE?OQ:/= M**\XT/XJJ[K#K=L(P>//@R0/JO7\ORKT*WN(KN!)[>198I!N5T.016,Z'K$ZAI]_,CCJ8QTY*>#]`NO%5_*DU]<1VT"AI'#DL2>@&?H:],T3P=I^A M7?VFUENWEVE5(4.>G;KUKD]5^&47V9WTC4+R.=1E4EEW*Q],\$?6KBHO= MV,YRG'X8W^9WM%?.IO;V,E/M5RI4X(\UN#^==5X,\+3^*1-@&1^=;2P_*KMG+#&NI+EC'7U/8**QM"\+V/A]Y7LWN6:4`-YLQ?I[ M=*V:YW:^AVQ;:U"BBDI#%J.:>*WC+SRI$@_B=@H_,UY]XK^))MYI++0BC.IV MO=,,@'T0=_J>*Y[3/">O^,"+V[G=8'Y$]TQ.[_=7T_(5O&AIS3=DR2J3_.K= M>!ZYX8U+P]*OV^#",<)-&=R-^/8^QKM?A(TLAU1GDD95\M0&8D#[U$Z"4>:+ MN*EBI2G[.4;,](HHHKG.T***R_$NI'2?#M]>*!^I%-*[L*344VS MRWQUKQUGQ#)'&^;6T)BC`/!/\3?B>/H*P8S@BJJGU.3ZU,C5Z$J,4D?,5IN M4#O3;)@F3V=Y-I]Y#=VS;)H7# MH?<5[_H^IQ:QI-M?0$.@;']T]Q^!R*\,TSPSK6L@-8Z=,\9Z2.-B?F<9_"O M5O`6DWVA:9-8:C-;,XD\Q(XI-Q0$<@\>H_G7%B7%K?4];`J<6TUHSJJ**SM9 MUJVT*T6YO!(8V<1CRUR??%M,Z7IS]Q M.P_-?_K5Z#7`_%H?\26Q/_3S_P"RFM:'\1'/BOX,CRNO>?""!/".EC_IW0_F M,UX-7OGA88\*Z7C_`)]8_P#T$5TXOX4<.7_&S6HHHKA/6"BBB@`HHHH`**** M`"N*\:^.TT3=8::5DOR/G<\K#]?5O;\ZO^-_%`\.:5B`@WUQE80?X?5C]/YU MXS%%/J%ZD4>Z:YN),#)R68GN?K730H\WO2V.'%XEP]R&YI:/H^H^+=7=4=I) M&.^>XE)(0>I/\A7L'A_PKIWAV`"TB#3D?/<.,NWX]A["I/#>@0>'=(CLX0#) M]Z:3'+OW/^'M6M4U:SF[+8TP^&5- M*_AQ!>(]YH:+!*5&21 M#M96&"I'8UW7@[XA2V+QV&M2-+:GY4N&Y:+_`'O5??J*V?B/X36\M7UBRCQ< MPKF=5'^L0=_J/Y?2O*J]!.->&IY$E/"U-'_P3Z15E=0RD,I&00>"*6O-OAGX MI9B-#O'S@$VK,>PZI_4?C[5Z37!4@X2LSUJ5558\R"BBBH-3ROXM+C6-/?N8 M&'Y-_P#7KBM._P"0I9_]=X__`$(5V_Q;_P"0EIO_`%Q?^8KB--_Y"EG_`-=X M_P#T(5Z5'^$CP\3_`!V?1-%%%>:>X%8?B/PI8>([8BXC$=R!^[N$'S*??U'L M:W**:;B[HF45)6D?/&J:;<:/J4UE=KMFB.#CHP[$>QKH_`/BJ31=32QN9";" MY;:03Q$YZ,/0'O\`G6[\6=,7R;+4D7#AC!(?4$97^1_.O-*]*+5:GJ>+-/#U MO=/I&EK*\,7[:GX:T^[2$;SZL.#^HK5KS6K.Q[<7S),****0S`\])3< M#RJ#[WYY`_&NQKR?XL2,?$%G&?NK;9'U+'/\A6M"*E-)G/BYN%)M&)X)T2/7 M?$D%O.NZWB4S2K_>`Z#\217N*J%4*H`4#``[5Y'\++E(?%$L3D!I[=E3W((. M/R!_*O7JTQ+?/8RP"2IW04445S':5=1T^#5+":SND#Q3*5((Z>X]Q7$_"NW: MT_MJ"3[\4ZQM]1N%>@53LM+M-.FNI;6$1O=2>;,02=S>M6IVBX]S*5.\XS[% MRBBBH-0KC?BE.8O"8C!_UMPBGZ#)_I795Q'Q60MX9MV'1;I<_P#?+5I1^-&& M)_A2/)0<5*K5#2@XKU3Y]JY:5ZG28BJ2M3P],SLUL7Q M4GJ:JRS@=ZCFN,#K75^!_`F@_(G1IS_1??OVK*I54$;T,/*I( MR?#WA;5/%,W^B)Y=JIP]S)]P>P_O'V'Z5Z-:>%O#G@RW2XNT^UWG\+S`,S'_ M`&5Z#Z_K6[JVIVOAO3$C@B16"[(($&!^78"O/+N[GOKE[BYD,DK]2?Y#T%>1 MB<9+9'JL?\`Z"*Z<7\*.++_`(F:M%%%<)ZH4444`%%%%`!2,P52 MS$``9)/:EKG?'>HG3?"-ZZ'$DH$*$>K<'],TXKF:1,YA6]RE9'CX9.K7YI>IW%%%%><>T%%%%`!1110`4444`(P#*0P! M!X(/>O!O%FC?V%XCNK1!B'/F0_[C<@?AR/PKWJO-OBW8C&G7ZCG+0L?_`!X? M^S5T8:5IV[G'CJ?-3YNQYW;7,MG=17-NQ66%PZ,.Q!R*^@M*U"/5=*MKV+[D M\8?'IGJ/P-?/%>O_``NO3<>%F@8Y-M.R#Z'##^9K?%1O%2.7+YVFX]SLZ*** MX#UCRWXM_P#(2TW_`*XO_,5Q&F_\A2S_`.N\?_H0KM_BW_R$M-_ZXO\`S%<1 MIW_(4L_^N\?_`*$*]*C_``D>)B?X[^1]$T445YI[84444`<=\4-O_"(G/7[1 M'CZ\_P#UZ\>KT7XKZNLDMII4;9,?[^7'8D84?ED_E7`6EI-?7D-K;KNFF<(@ M]S7HX=6IZGBXQ\U:R/:?A^K)X)T[=W5R/IO:NCJKIMDFFZ9;6<7W((UC!]<# MK5JN"3O)L]>G'EBHA1114EF'XS_Y$[5/^N#5X37NWC/_`)$_5/\`K@U>$UW8 M3X6>3F'QKT/4OA)_R"M1_P"NZ_\`H(KT"O/_`(2?\@K4?^NZ_P#H(KT"N:O_ M`!&=V%_@Q"BBBLCH"BBB@`HHHH`^?O$/_(R:G_U]2?\`H1KU/X9?\B=%_P!= MI/YUY9XA_P"1DU/_`*^I/_0C7JGPS_Y$V'_KK)_Z%7=B/X2/)P?\=_,ZVBBB MN$]8*\T^+5@V_3]0493#0.?0_>7_`-FKTNL_7-(AUW2)["XX65?E;NC#H?P- M:4I\DDS&O3]I3<3P.SNYK"\ANK5RDT+!T;T(KW#PMXHM?$U@)(R([E`/.@)Y M4^H]0?6O$]2TVYTG4)K*\C*31'!'8CL1[&FV%_1W5E,T,\9^5E_D?4>U M=U6DJJNCR:%>5"5GL?15%A1EH0)A_P$Y/Z9KI*9-$D\+Q2 M#Y\X45=UG2Y-&U>YL)0_M7N+M!I]F6(6*"!.@&`J@=`*S_"^@Q>' M-!M["/!=1NF=.T6%'7$LG[QQZ$]OP&*VP\;SOV-L/&\[]C6)`!).` M.YKR+5+W^V?$-S=@YC9]L?\`NC@?X_C7;>.=<_L[2OL<+8N;L%1CJJ?Q'^E< M1I=OC!Q6M>5WRE8J?-)4UT-BUBVQ@5;6/-1Q#``JX@&*S2'%%9H\5!(E7I`* MJR4F@:.C\,ZD;B`VDK9DA'RD]U_^M6[7GME=FQU"&X!X5OF]U/6O0000".AK MJHRYHV.FC+F5A:***U-0HHHH`*X+XM?\@2Q_Z^?_`&4UWM<%\6O^0)8_]?/_ M`+*:UH_Q$<^*_@R/*J]]\+?\BMI?_7K'_P"@BO`J]]\+?\BMI?\`UZQ_^@BN MG%_"CBR_XF:M%%%<)ZH4444`%%%%`!7`_%J8KHUA"#P]P6/X*?\`&N^KS_XM MQDZ5I\G99V4_BO\`]:M:'\1'/BOX,CRVO9?AF`/!L&.\LF?^^J\:KU[X63B3 MPJ\>>8KEP1]0#_6NO%?`>=@'^]^1VE%%%>>>R%%%%`!1110`4444`%AXS7IOPB8_9- M47L)(S^A_P`*\RKU'X20E=+U&8CAYU4'Z+_]>N[$_P`-GE8+^,CT&BBBO-/; M/+?BW_R$M-_ZXO\`S%<1IO\`R%+/_KO'_P"A"NW^+?\`R$M-_P"N+_S%<`C, MCJR$AE(((Z@UZ='^$CP\4[5VSZ0I:\=L_B1XBM%"S+%<@<9EA(/YC%7U^+.H M@?/I=N3[,PKC>'F>BL;2>YZG6)XG\3VOAK3S+*0]PX(AASRY_H!W->?W?Q5U M>9"MM;6ML3_%@N1^?'Z5S5LS>(-=C&K:B8VG;:US*-VWT'L/T%7##/>>QG4Q ML7[M/#]+\.J'MHS+@^E;U*K7YERQV'A\)R/GGJPHHHKF.X M****`,/QG_R)^J?]<&KPFO=O&?\`R)^J?]<&KPFN["?"SRAZE\)/^05 MJ/\`UW7_`-!%>@5Y_P#"3_D%:C_UW7_T$5Z!7-7_`(C.["_P8A11161T!111 M0`4444`?/WB'_D9-3_Z^I/\`T(UZI\,_^1-A_P"NLG_H5>5^(?\`D9-3_P"O MJ3_T(UZI\,_^1-A_ZZR?^A5W8C^$CR<'_'?S.MHHHKA/6"BBB@#G_%?A.U\3 M68#$17<8/DS@=/8^HKQG5-)O-&O6M+^$Q2KT]&'J#W%?0U9VLZ'8Z]9&VU"$ M.O56'#(?53VK>C7<-'L&Y#*SP3QW,"30NK MQ2*&5E.00>AKSZM)TW8]BA7C6C=;DE%%%9FX4444`<+\2?##:E9+JMG&6N;9 M<2JHY>/K^8_EFO)Z^D:\O\<>`7MY)=3T:(M`V6FMT'*'NRCT]NW\NS#UK>Y( M\W&89O\`>0^9Y]11UHKM/+(Y6P*ZCX6Z0-2\6BYD7,5BAEY_OGA?ZG\*Y.'[R\(^:XN-N?90/ZDURUY61W8.%YH]!KSOQE.9O$$B9XA14'\S_. MO1:\O\1DGQ%?9_YZ?T%>1B7[IWXI^X9M%%:>B:%<:W/\@,=LI^>8C]!ZFN*, M7)V1PQBY.R+7A713J=^+B9?]%MVR<]';L/ZFNWU?5K;1=/DN[IL*O"J.KMV` M]ZJ7^IZ9X3TI%9:KK%YXCO\`S[H[8UXBA4_+&/ZGU-=B M:HQMU.F=6.'CRQUDPN+RXUO4Y+VZ^_(>%'1%[*/I6M:H(U%4;6(1@5>1JYKW M=SGIJVKW+T;5.LG%44>I!)5)FZ99:3-02-33)43O0V#8R0YS7?Z+.;G1[60] M3&`?PX_I7GCM7<^%B3H$&?5O_0C6M!^\:4'[S-BBBBNLZPHHHH`*X+XM?\@2 MQ_Z^?_937>UP7Q:_Y`EC_P!?/_LIK6A_$1SXK^#(\JKWWPM_R*VE_P#7K'_Z M"*\"KWOPH=WA32S_`-.L?_H-=.+^%'%E_P`3->BBBN$]4****`"BBB@`KE?B M/8F\\'W#*,M;NLP^@.#^A-=545S;QW=K+;S#='*A1AZ@C!JHRY9)D5(\\7'N M?.5>A?"74`E[?V#''FHLR#W'!_F/RKB-5TZ72-4N;&<'?`Y7/J.Q_$8-2Z#J MK:)K=K?KDB)_G`_B0\,/R->E4CSP:1X=&?LJJ;/H*BHX)H[B".:%@\6>^%%%%`!1110`4444`%<-\5[D1^'K:WS\TUP#^"@G^HKN:\C^*.J M"[\0164;92SCPW^^W)_3;6U"-ZB.;%SY:3\SB:]M^'^GG3_!]H'&'GS.P/\` MM'C],5Y)X>T=]=UNVL4!VR-F1A_"@^\?R_F*]^CC6*-8XU"HH"J!V`K?%3T4 M3DR^GJYCJ***XCU#RWXM_P#(2TW_`*XO_,5Q&G?\A2S_`.N\?_H0KM_BW_R$ MM-_ZXO\`S%<1IO\`R%+/_KO'_P"A"O2H_P`)'B8G^._D?1&`>PI"BGJJ_E3J M*\T]LY+QOX/CUZQ-Q9QJNH0#*8&/-7^Z?Z5XVRE&9'4JRG#*PP0>X-?2-><_ M$;P?YH?6M.C^=1FZC4?>']\>_K^==>'K6]V1Y^,PW,O:1W%^'GC/SQ'HVIR_ MO0-MM*Q^^/[A/KZ>O2O1:^;@Q4AE)!!R"#R#7KW@/QD-;MQ87[@:A$O#'_EL MH[_4=_SHQ%&WO1%@\3S?NY[G9T445R'HA1110!C>+T,GA'5%'7[,Y_(9KP:O MHG4;;[9IMU;8_P!="\?Y@BOG;:5^5A@C@BN["/1H\K,5[T6>H?"-P=/U).XF M0_FO_P!:O0J\M^$MV$U+4+4G_61+(!_NG!_]"KU*N?$*U1G9@W>B@HHHK$Z0 MHHHH`***ANIUM;6:=_NQ(SGZ`9H`\`UJ3S==U!QT:YD/_CQKU[X=Q>5X*LL_ MQEV_-S7BLDAD=Y&ZN2Q^IYKW[PY9G3_#FGVQ&&C@0,/?&3^IKNQ+M!(\K`J] M24C3HHHKA/5"BBB@`HHHH`9)$DT;1RHKHPPRL,@CT(KRKQMX".E+)J.DH6LQ MS+#U,/N/5?Y?3IZQ2,H92K`$$8(/>M*=1P=T8UJ,:L;,^;J],^%>O-(D^CSM MGRQYL&3T7/S+^9!_$UR?C;0ET#Q%+#`NVVF'G0C^Z#U7\"#^&*/`D[6_C/3B MO\;M&?H5-=U2U2G<\FBY4:Z3[V/%><--S MEJX2G4UV9\QSG#$'@CM7N'PQC$?@2R(_C:1C_P!]G_"M^\T33=1R;W3[6I^@IFI^/XH(?LN@6P"J-JRR+A5'^ MRO\`C7)-;M+(7E=G<]68DG\ZD2!5[5R^U45:"L<'M96M!6_,@E^T7]RUQ>2O M-,W5W.3_`/J]JL1Q!*D``HK%MLS44M25&J=7JH#BGJ]"9HF75>G>950/3O,J MKEE<*/Q MKU:*-8HDC085%"@>PKHPRNVSHPRNVQ]%%%=9V!1110`5P'Q;/_$HT\>MP?\` MT$UW]>=?%V0"TTN//)DD;'T`']:UH?Q$<^*_@R/,J]W\&/O\'Z6?^F"C\N*\ M(KV;X;7JW7@^",,"]L[Q,/3G(_0BNK%+W4<&7NU1KR.LHHHK@/7"BBB@`HHH MH`0D*"20`.234%E?6VHVJW-G,DT+YVNAR#@X-8GCC7(]%\.7'S`7%RIAA7N2 M1@G\!S^5'@"W^S^"M/'0NK/^;$_RJ^3W.8R]I^\Y%V,3XE^&&OK8:O9H3/;K MB=5'+1^OU'\OI7E=?2)&1@\BO*_&_@*2QDDU+1XB]JY(XL9AFW[2'S+7PV\6K&%T2^DP,_P"BNQ_\<_P_+TKTNOFT'&"#@CD$ M5Z3X2^)"A$LM?<@CY4N_7V?_`!_/UHKT'?FB&$Q2MR3/2:*9'*DT:R1.KHPR MK*<@CV-/KC/2"BBB@`HHK+USQ#I_A^U,U_,%8CY(EY=S[#^O2FDV[(3DHJ[# MQ#KD'A_2);V<@E1MC3/+N>@_SVKP:YN)KV[EN)V+S3.78^K$UJ^(O$5[XJU- M9)%8(#MM[=,G;G^;'UKNO!'@'^SFCU+6$!NA\T,!Y$7N?]K^7UZ=L$J$;RW/ M+J.6+JY_^M77445QRDY.[/2IP4(J, M0HHHJ2SRSXMG_B:ZQ.-0M3Z3)_P"A"NS^+$@;Q!9Q@\I;9/XL M?\*X>)_+FC?^ZP/Y&O3H_P`-'AXE_OV?2%%-5@Z*PZ$9%.KS#W`I"`1@C(I: M*`/(/'W@[^Q;DZA8)_H$S?,H'^I8]O\`=/;TZ>E&K_*!I+"4_N9#V_V6]Q^M=U" MMS+EEN>3B\-R/VD-CTGP;XOB\26?ES%8]0A'[V,='']Y?;^5=/7SI9WD^GW< M5U:2M%/$=RNO;_ZWM7LWA'QC;>)+81N5AU!!^\AS][_:7U'\JRKT.7WH['3A M<4JBY9;_`)G2T445S':%>%^-=).C^*+N(+B*9O/B]-K<_H5^%=7&A^([2\D>`?'$:PQ:1JT MH0IA;>=SP1V1CV]C^%=&)IN7O(Y,%74'[.1Z1124M<)ZH4444`%BV+75_,L<:]!_$Q]`.YKQ/Q%KMUXIUHS MF-L$^7;P+R5&>![D]ZWH4W*5WLCDQ=90ARK=AX4TAM;\1VEKMS$&\R7V1>3^ M?`_&O>:Y;P+X5_X1W33+=`?;[D`R=]@[*/Z^_P!*ZJBO4YY:;(>$HNE#7=A1 M116!U!7->"==N=>L;Z:[=&:*[>-`JXPF`0/UKH9VV6\C?W5)_2O)OAIXACTW M59K*Z<)%>X*,>@D'0?B#CZ@5K"'-"3.>K5Y*D$]G<]=HI*6LCH"BBFNZQHSN MP55&2Q.`!ZT`>9_%T)]KTL\;]DF?IE:Y_P"']HUWXRLB!\L.Z5CZ``C^9%1^ M-M?7Q!X@DF@.;6%?*A/]X#JWXG],5W7PT\.OIFFOJ-TA6XO`-BDWE;=#^]D_H/>FDY.R'%.3LC9\$Z26D?4I5^492'/<] MS_3\Z[2HX(8[>%(H5"1H`JJ.PJ2O2IPY(V/4IPY(V"BBBK+"BBB@#(U3Q3H^ MC3^1J%]'#-M#>602V#TX`KRGQUXF@\1ZO&]H6^RVZ;$+#!8DY)QV[?E7LL]A M:73A[BU@E8#`,D88X_&F+I=@GW;*V'TB7_"MJ=2,'>VIS5Z4ZJY;V1\[[AZB MM#1]?O\`0;@S:=?]`VV_[^G_``KT@Z58'K8V MI^L2_P"%-.C::>NGVA_[8K_A6?M*7\IM[&NOM_@><'XN7W;3;;_OXU,;XM:F M?NV%F/J6/]:](.A:4>NF67_?A/\`"FGP]HYZZ78_]^%_PH]I2_E#V-?^<\RD M^*NMO]R&Q3Z(Q_\`9JH7'Q$\17`(^W+$#_SRB4?K@UZT?#6BGKI-C_WX7_"D M_P"$9T3_`*!-C_WX7_"J56DOLD/#UW]L\*GNKW5KM3//-=7,A"+O8L23T`KW M_3+0:?IEK:+T@B6/CV&*CMM%TVRD$EK86L+CHR1*"/QQ5ZLZU7GLDK&N'P[I M7Q]Q7G.K>#]:T8L;FR=XA_ MRUA^=/TY'XBO=Z*WAB)0TW.6K@Z=379GS_I'B/4]#?\`XE]X\:YR8C\R'ZJ> M*[&Q^+5PBA=0TZ.0_P!^%]OZ'/\`.N^O=`TK46MZA]`JG_V:H[CXLZ:@ M_P!'L;N4_P"UM0?S-7Q\,O#V?]5<'V\\U:@^'_ARWP?[.60_]-)&;^9J+T>S M-.7%=TNVSM((!_TSC"_RJU1[=1^!6#ZJYN]65SG_``[X-TSPX`\" M&:ZQ@W$O+?A_='TKH***PA:7<2P7>H(L\1P M\:JS,#Z<"MVJLNFV4\ADFL[>1SU9XE)/XXIQMU)ES6]T\.\5:XOB#Q!/>Q@K M"<)$K==HZ9^O)_&L?*GN*^B5TRQ3[ME;#Z1+_A3FT^T;[UK`?K&*ZUB5%62/ M/E@)2;DY'%^'?B5I1TNW@U25K>YB0(S;"RO@8R",UT^F>)M(UF=H=.OHIY57 M>47(..F>1[U9.D:>>MA:G_MBO^%2P6-K:L6M[:&%CP3'&%)_*N>3@]4CLA&I M&RDTR>BBBLS8*K7]A;:E9R6MY$LL$@PRM_G@U9HH!J^C/'O$?PYU#2Y7FTU' MO;/J`HS(@]"._P!1^5>,Y4\JRG^=?1U136L%Q_KH8Y/]]0?Y MUU1Q32M)7."I@(MW@['F6A?%6:W18=:@^T*.//BP'_%>A_#%=7;_`!$\-W"@ MG4!$?[LL;`_RQ6W_`&/IW_0/M/\`ORO^%']CZ=_T#[3_`+\K_A6!B0'3ID=:LTR*&.",1PQK&@Z*@P!^%/K$W5[:G M*^*_`MGXBSM>6ZQX7U;0V87MF_ECI*@W1G\1T_'%>^ M4A&1@\@UO3KRAINCFK82%5WV9XGH/C[5]$C6$2+=VR\".8D[1[-U'ZUUUM\6 MK!@/M6G7,;=_+97'ZXKJ+WPIHFH,6N=,MF8]65-I_,8K+D^&OAUSD6TR>RSM M_4U;J49:M&4:.(IZ1DFBF_Q6T8*2MM?,?38H_P#9JQ=2^+-Q(A73;%(<_P#+ M2=MQ'X#`_6NEC^&GAU#DV\S^S3M_2M2R\)Z'I[!K;3+=7'1F7>?S.:GFHK9- ME\F)EHY)'E%OI'B/QI>"XD6:8'_EO/\`+&H]O\`*](\+^!['PX!.Q^TWQ',S M#`3V4=OKUKI@,#`Z"EJ9UI25EHBZ6%C!\SU84445B=(4444`1SH9;>1%ZLI4 M?B*^>;_3KO2[@V]];R02+QAUQGZ'N/I7T545Q;07<1CN88YHSU610P_(UM1K M>SZ'-B,/[9+6UCR'0OB/JFD1)!=*M];KP/,;#J/0-W_&NJM_BOI+K^_M;R)O M0*K#\\UKW/@+P[=$EM-CC)[Q,R?H#BJ9^&7AXG_4W`]O/:K+Y/L5O"R0N?^/:V!8O_`+QZG]!7 MHEO\/?#EN<_V>)#_`--9&;],XK=M+&UL(O+L[>&!/[L:!1^E)5*<-8HIT:]3 M2N@HJ91 M4E9DRBI*S/);VQN=/G,5W"T;]L]#]#WJ"O7+BVANHC'<1)(AZJXR*P+OP1I\ MY+6[RVY/93N7\C_C7)+#-?"<<\*U\)P5%=5+X"N0?W5Y"P_VD(_QJ,>!+XGY MKJV`]MQ_I6?L9]C+V%3LNP[K&@7]3FMW3]!T_3<-;6 MZ^8/^6C?,WYFKCAYO?0N.&F]]#D-&\(W-\5EO0UO;]<'[[?AV_&NZM;6&RMT M@MXQ'&@X45-1753IQAL=E.E&GL%%%%:&@4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%% M%%`!16/XFUJ?0=)>]@L6NPGWP'"A!_>/?'TIOA+5Y]=\/PW]TL:22L_RQ@X` M#$#K]*KE?+S=".=O,_&=I=MXXT>W?4[DK<2!HR,#[.2^/E`'7W/-=II6A7 M.G79FFUJ_O5*E?*G*E?KP.M:2@E%.^YC"JY2<;;">,?^10U7_KW:J7PZ_P"1 M)LOK)_Z&U7?&'_(H:K_U[M_*N9\&:)=ZOX2MO/U6ZMK0%Q'#:$1D_,=:;<:EX7\>P:+/?SWMC=+E/.;<1D'!]B",>A MKT6HG#E-:=3G3TLT%%<3KOB=)O$3:.-0>PM+==US<1*6D=NR*0#MZ\FLC6]6 MM-)2&[\,:GJ$UTL@\R"4RR1R+WSO'\O6J5)LB6(BK^1Z;14%E<&[L8+@H4,L M:OL/5.9TD@A<8CC.['('WL8SS4PAS.Q=2IR1YK7 M/2**Y;3?#.L6?B8:A=:]+=VQ0AHF!7<2.FW.T`=>*T?$NIWNEZ7OTRQDO+N1 MA'&BJ2%)_B;';BDXZV3!3?*W)6-BBN(U_P`/WJ^')=2DUG41J4$/G-MFVQY` MR5"K@`=I`1^&+R>PO'M984,A9`"6`ZKGM]17.>#-(O=9\*1--J]W;VYDDVI;$*[' M<'/1 M@.01UKTR.198ED0Y5P&!]0:4XM4J M39$L1%7\CTZBH;6?[3:0S["GF(K[3U7(S@UP8FOK7XJ6VGOJ5W/:E3*LZFDFE>63<\C%B?F/T]_DL=/4%K>V][YWV:59/)D,4FW M^%QU'ZU1\1PW$NB7)M;V6T>.-I-\0&3A2<9(X^HYKB/`.AW6I^'WN(M:O[,& MX8&.!AM)P.>0>33C!.+DV3.HU-12/3*SI=`TR?5DU.6SC:]CQME.&,#KTZF ME"+;=F.K-12;5]3T2BDKE=3UB\U3Q+_PC^CS?9_*3S+R["AF01S[^ MU*,6RY343JZ*Y74?!;RVS/I^L:I#?*,I+)=.P8_[0_PKH;".XAT^WCO)!+<) M&JRN.C-CD_G0TK:,492;LT6:*X2*_P#^$A\H7L]O;6OR6]M%*8O-(ZD MD8)/?%;^AZ3>Z1J5Y&UW-@5SWBKPA#XF^SR_ M:7M;FWSLE09XZX(^HJWH^D7MBWF:AJ]Q?R;=BAE"(H]<#J?[52^'7_(DV7UD_P#0VK0U[1)M/5)];NS>Q8\MQ$@"`=`!C'-KHZR-UEC5XV#(PRK*<@CU% M'?^`?^AFN_1%C1410JJ,``8`%34M6CU*XUJZ^U0D&%E MC0",`Y``Q4TFD[LNO&4HI)'65C^)?$=MX9TS[7O8<5H64, M]O;!+JZ-U("(/[;OO"-[>7ES!90FW+_98$WLP(Z,Y_H!]:T/AVNWP38^Y<_\`C[5' M;>"Y7TPV&K:U>7ML$V)$N(U4=LXR6QQC)Q[5+X;\)W/A\B,ZQ<3VB,6CMQ&% M7)]3R3].!FM)./(XWZF$8S513:Z6W+GB_P#Y%'5?^O9_Y5G?#?\`Y$JU_P!^ M3_T,UH^+_P#D4=5_Z]G_`)5R7@+1]6;08[O3]:^S0S.VZ![<2*"#C(R>#Q1% M)TGKU";:KJROI^I8^*0-Y;Z5IT"[[JXN#L0=<8Q_-A7<6D/V:SA@SGRHU3/K M@8K,T[PY#::@VHW<\M]J++M^T38&P>B*.%%;-1*6BBNAK"#4G-]3SGPI?KI? MQ"URPO6"27";D*L6K:]?7]H/\`EV)*HX]&Y)(]JN;C/WKV9G352G>- MKKH=6CK(BNC!D895@<@CUKS^]8)\9[0L<`P@#/KL:O0%4(H50`H&``.`*YOQ M-X,BU^]@OH;N6RO80`LJ#.0#D>G(/?-33DDW$]4)(`^ MS/\`RK*^&G_(F6__`%UD_P#0C3KCP?=W^ES6^IZU'$51JEU.@);R<*L63U..OZU5XJ#CM,X[XI1:Y'%LN^AB\F!(@S MOL4+N=LL<=R>YKEKOP-)?:O'JD^MW1O(L>6ZQ(`@'0`8QW-*FTF[A7C*222Z MG6UYOH-\FD_%#6+:^;8;QR(V;@9)W*/Q!KT.VCDBMXTFF,TBKAI"H7)MDLQ>"Z0;5GCQG'H1W%%.25U+9CK0E*TH[HZ"H[>XANX5FMY$EB M;.'0Y!P<'GZBN4M/`]ZJ""_\2:A_T;5R9+FP(`D)R2,D$$]^G!]ZNVOA:^TFXN3H^LF"VN)#(8)K<2A& M/4J'H-#^T2B62XN[I]\]Q)CYGGNH62-886?GIR0,#KWK-^'UV]GHUOI5Y9WMO M GRAPHIC 16 image_002.jpg GRAPHIC begin 644 image_002.jpg M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX. M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_ MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T] M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`!*`0X#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V,<51U36+ M/28M]W*%ST0*JQ]Y'MMI>6]_;I/;2K+$XR&4U./TKQ7P?X MDET'5XXGJW:P3;#AGR>>M>E:?9"S MAQY\TQ8#+2MDU;A9)F,:O-)Q[%OUH[BE[4AXJ#8.W-(!535-4MM'L9+N\D"1 M)^))]!7,V5QKOBU?M"2G2M.;[FT9E<>N>PJE&Y$JBB[+<[#&?'@U"\_L[5XA:WP^4'H&/]*[)T\Q&3)&1U'44.+B]2J=2-17B.X-' MUKS+QS/J&A:Q9PV&J7B17*Y8%\X.<<5TT/AB:6UCD.MZD)&4'=YO&?RI\B2O MW,_:MR<+:HZ?-&[\J\[UB]\1^"YH[A[PZE8NVTF0?,/:NUT;5H-:TR*]MON2 M#D?W3W%*4&DFMBHU4Y.#T9?[GWI,\U6OK+[;#M\^:$@'#1-@UYEX>O=5U#QB M^F7.K79AA9L@/R<4XPYM>P5*O(UIN>K=_K2].E,BC\J)4W%@HQECDFGXX(SU MJ#1>@>]%>??$(WNA6]OS>UL8]]Q-.[H&9I6RP%"6EP<[2Y4CJ0P]0?I3@?3FN)O/#=UHM_9W.FZC>&V\T"6) MVW<&NU''TH:2",I/1JQQ?Q2G=/#4<:9`DF4D^PKRV&X*'BO8_'FE/JWA>=(Q MF2(B50.IQVKQ,=,'J*[<*_^(]0^SV2CCF2 M5ONQCZUCJLLTL<$()DE8(H]2:]6N+*/PCX3@L+;BXN/];(/O$XY_PIXBNJ4; MF.'H.I=R>B.=.EZ1I+&*&,7URO#S3?VT:`Y8@&7'8"O&5>?+7Z5Y9\0O^1WLOHG\Z]4C M_P!6OTK>I_#B\;Q)X\M='R?LEO*%=<]3W->FQ0 MK#&D:`!$&`!VKR+2)/(^*$GG'YFN&7GU->P5O67*DEV.3#/FE.3WN`%(0>32 MGBC-8'7L>8?%#2!:7=KJUL-CNVU]O'S#D-7;>$]4;6/#EK=.\P;:D^&D;)X3C9N`[DK]*W?O4M>AQIC6G%G#_`+@_E7G'Q4)&M:85&65,@>OS5T=MXEU".Q0R:%<_(@Z.#D8I-7IH M:FE7EDKU@_=/TKR?PA_R4R\_WI**6S#$;Q]3UBEI,TM8'4<#\5_\`D%67_7;_ M``KM[7BR@_ZYK_*N(^*__(*LO^NW^%=Q:_\`'G!_US7^5:OX%\S&/\67R.1^ M)VFS7V@17$"LQM7WLJ]<'O\`A4G@SQG;:Q9Q6ERZQ7D:A=IX#X[BNMD19$*. M`RL,$'H:\U\5_#V2VE;4=`!&/F:!3R#ZK_A3@XR7(S.M&<9^T@>E''2EW#'% M>?>!_&\EW.NE:LQ\\<1RL,;L=C[UZ"*F<'!V9K3JQJ*Z`C(PPR#P:\U\7_#N M5[F6^T5`VX[G@Z<]R/\`"O3,4`8HA-P=T.I2C45F>(^$-(N/^$WLXKVUECV$ MO\ZDJQ_P"K7Z5YGXJ\+^(?$&O&_ALHXE4*$5I@3QWKH[2_ M\6P6Z)/H]O(RC&5G'-;RM*$5?8Y(-QJRDUHSK*9+(D49DD8(B\EB<`5S3ZMX MI_AT.+\9Q6?=GQ?K!2SN=/MK:SD8>:RR9;;Z5GR>9NZO9,Y_Q_I5/<&I[G3[>^T\VEW&LL3+M*FN'_X M0S6?#=\UUX9NEDB8\V\IQN^M:)==B41W MGAZ5I.YBD&VGS77B?55\JVM(M-B88,TK[W'T`K/D9LJJ[&%\0[I];U2Q\/V! M+S;M\NWG;]?YUW.D:>FE:7;V<8&V)`/Q[FJ&@>%K70P\H9I[R7F2XDY9C6TV M0"0N3C@9ZT2EHHHFG3?.YRW9YK\4C_Q/=)/HO_LU>BVF#90_[@_E7`^,O#VO M^(]6@N+>Q2..W7:NZ8?-SG-=CH\M^;:*&]L?LY2,`MY@8,1]*N5O9I(B-_:M MM'%^-_#D^D7R^(M$S&Z'=,J]O?Z5U/A3Q1!XDL`P(2Z0?O8\]/<>U;KQK(C) M(H96&&!Z$5Y[J'@74=)U?^TO#$RCYL^0S;<>V?2A24X\L@G"5.7/#;JCT2O) M8S_PCWQ2?S_DCFE)#'^ZU>@Z;J&LRHBZAI2Q/_$Z3J5_`56\5>$;?Q+`KA_) MO(_N2@?H?:E3:B]2JL74A[NZ.A4@X/K17%Z?>>*-!B%K?:>NH0H,1RQ.`S?6 MK;ZYX@OHMECH9MY#_P`M+B0$+[X%2X,N-5-:HRO'[?VIKNCZ/#\\ADWR`?PK MZUWJ($B5/[H`KG_#_A?^SKJ34=0G-UJ4WWI2.%]A71$8%$FK)"IIWM]5T58YECB\N2%FQN%31>)M89!&?#LXE(ZF M4;Z9%9>+=,NK-0DMQ(I95[MGK7IR;O+7=]['/UKEM/\` M#=[?ZVNL^(#'YT8Q#;IRL?XUUGTJYRNDNQ%&%IREW'4445D=`AI"*=24`8.L M^%;;4F,T)\B<]6`X/U%XC8;94'8L!S^=)Q$JB>QOTM9-R\FGV$2S M:@Q>63'F,OS'/\(%4%U.Z?PA=W8G(N(F95DX)X('-%M!\VO*=)FEZU@6T]Y! MK=K";EKF"X@:1]P&8R`,8QZTVPO;W4+KSDO(4B6U3_C63>74UOK6DVZ3'RYO-$@('S87(J)+U[[4;V`W9M3 M:R!0HQ\PQG//:E8;>ES;SFC&:PM1U"XMM4AW2LMDP5-\>#AR>C#WK<'M18%) M-V'T444B@HHHH`****`$I:**`"DI:*`"BBB@`HHHH`****`"BBB@`I*6DH`@ MELX)KA)I(P94&%;N!3&T^V=Y':(%I!M<_P!X>]6'Z4O\7X4"L5WT^UDM5MGA M5H5^ZIZ#Z4-I]LUJ+=H@8?[AZ59[T#J:`LB":R@N(5CEC#*ARN>QK/U72P^A MW=K8P@/./N@X&K` M=3Z_6K([T?Q4[A8J3Z7:7,C/-`K.Z[')_B'O3Y;"WFMT@DB#1H05'ICI5D]1 M3<\FE<+(B>T@EDCD>,%XON'N*9+IUK-<">2%3*/XL GRAPHIC 17 image_003.jpg GRAPHIC begin 644 image_003.jpg M_]C_X0[[17AI9@``24DJ``@````(`!(!`P`!`````0```!H!!0`!````;@`` M`!L!!0`!````=@```"@!`P`!`````@```#$!`@`=````?@```#(!`@`5```` MFP```!,"`P`!`````@```&F'!``!````L````"T!```L`0```0```"P!```! M````061O8F4@4&AO=&]S:&]P($-3($UA8VEN=&]S:``R,#`W.C`Q.C(Y(#$U M.C,U.C`W```'``"0!P`$````,#(R,`&1!P`$`````0(#``"@!P`$````,#$P M,`&@`P`!````__\```*@!``!````R`````.@!``!````-P````6@!``!```` M"@$````````"``$``@`%````*`$```(`!P`$`````P`````````!`0$!``<` M`P$#``$````&````&@$%``$```"'`0``&P$%``$```"/`0``*`$#``$````" M`````0($``$```"7`0```@($``$```!,#0``$P(#``$````"`````````,#& M+0`0)P``P,8M`!`G``#_V/_``!$(`"P`H`,!(@`"$0$#$0'_VP"$``4#`P0# M`P4$!`0%!04&!PT(!P<'!Q`+#`D-$Q`4$Q(0$A(5%QX9%18<%A(2&B,:'!\@ M(2(A%!DE)R0@)QXA(2`!!04%!P8'#P@(#R`5$A45("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(/_$`:(```$%`0$! M`0$!```````````!`@,$!08'"`D*"Q```@$#`P($`P4%!`0```%]`0(#``01 M!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*%A<8&1HE)B7J#A(6&AXB) MBI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9 MVN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ`0`#`0$!`0$!`0$!`````````0(#!`4& M!P@)"@L1``(!`@0$`P0'!00$``$"=P`!`@,1!`4A,08205$'87$3(C*!"!1" MD:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*CI*6F MIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V M]_CY^O_:``P#`0`"$0,1`#\`^L/&WC72O`.@2ZQJ\I6%"$CC7EY7/1%'+4_"T'EX1(KEPWJ M28P1^&T?G7CL7CB2"S,9`V@==U>W@<#"=%5'JV?)YMF]6CB716D4EMU=KGTE M\-OVF++Q1X@A\.^(+"+3+RXCE)BFD_N$$90GC')R>..,^R5\5W'PBFTV MTT[4/%TLUO/>J9AIENRK-'%QM:1R"$)Y^7:>AR0>*^F/'?C_`%?PS<:`;&UM M9([Z&62YCE4DKM$>`I!&/O-V->7F%;"4YM4GMN=N5XW$*E+ZWNK6[V??\/,[ MRF32B"%Y2KL$4L512S'`Z`#J?:L7P=XPA\6VTS+;/;3P$"2(MN`!S@@X&>AK M=KFA-35X['NPDIKFCL^+?AGQ5J]QI.DR:C<7EK(([J/^S9T^SMDC$A9` M%Y!Z^A]*ZVO'_@D`/BY\50/^@A;_`/M:O8*WK0C"24>R_%7,<-.=2#'DO9;'2DU'7[B`[9UTBT:Y6$^C.OR@]>,YX-BZB^/+M= M6MFM7D_W=XPWX&NNN)A;0/,R2.$4L5C0LQ]@!R365XQ\(:5XY\/76AZQ;K-; M7"8SCYHV[.I[,.H->7?LH^.=7\0^'=4\-ZSNDGT"2.*.9VRQ1MX"'_=,9&?0 M@=N:]E&=-SCI:UUZD>WG2K1I3UYKV?IT?R_X8ZZS^.W@W4;BYM;&36+N>T;9 M%_',MQ!H6JI MV,UK&A3G45-:75[_`"OV.>IBZU*@ZSL[2:M;?WN7O^AZ_P"(/$-IX9L6O;V* M\:!%+.UO:O-L4#))"`D#%4?!7C_0OB#8RWWA^>>YM(GV&9[62)6;N%+J,X[X MZ5J:W_R!KT?].[_^@FO-_P!E4#_A3&F?]=Y__1K5A&$72E+JFOQO_D=&]=K=/2O*=&\60?!;X MU^*;3Q<)(;'Q/<)=6.I$?NU`+81CZ#?MSVV@D8.1[N(T#F0*-S``GU`SC^9_ M.KJ4U3BM-UO^?W;&="M*K.2O;E;35M?+[]^W3S/,/VA_@W=?%C0[*73+M8M2 MTOS6MX7'R3APN4)_A/R#!Z=CUR/G+X#?#QO$OQET_2=:M)8$TT/?7-M/$59C M&5VJRGH-S+G/88[U]O45K1QLZ5)TNG3R.?$Y52KUXUMFGKYGS/JEK%K/B/5M M;\1WW]G6`NY-SE=TDQ#$"*)?XF``'HHP3[V9/&EUXH\0W.NZ@BQ-*JQPVZMN M$$:YPH/?DDDX')KH/C)\+KFVU.;Q'H]M)/#=,7NXHX\F)L#YN.2#R3QQ^->6 MHS(<(3D^E?(8ASHS<;;N_J>9B/:4*K3V;OZ_U_72WJW@'7F_X3S3TA'$^^-U M!ZKM)_0@'\*]KKRWX*_#J_T6637M:@,-P\?EVT+_`'D!^\S#L3P`.O6O46#% M"$(#8X)&0*]7`QDJ=Y=6>S@(S5.\E:[/(/@D0?BY\5P5Y+H7 MP/\`%?AGQ7J_B32OB%#!=:O,TMW$=$#Q,2Q8``RY&,D#G.*Z*?PK\295VI\1 M=-A/JGAU<_K,:]:JH3::DMEWZ)+L+#RJTXN,J;^)OIU;??S.`_:;O9_!_C'P M+XVCM9)[?3[J1+C;P,91@N>Q9?,Q]*]UCD26-9(V5D8`JRG((]17,^$/`1T7 MPU>Z5X@U$>(I]1GDFO[BXMP@N"P"X*9(`"JHQ[=NE-/U.P^UI&?]AA(A7KVZ]\U4I0G!4[_``[/O?\`K_AB:<*M.K*JHW4[ M75U=6T]'=;ZZ>9Z4[I%&SNRHBC+,3@`>M>(_LG:%?C3?$?B^\B,$6OWH>WB( MYVHTA+9[@F0@?[I]:[;5OACJ'C.9(_&GB,:CID;!UTVPM6LX)2#_`,M?WCLX M&!@;@/K7;LK"(K$51MN%)7(![<<<5"G&G3<5JW^%C5TI5:T:DE91OVU;5OP_ MK;7P#X3^%8_$OQ8^)[MJVL:>;?55`_L^\:`/NDG^\!PV-O&>F3ZU<\*W4GP# M^)%QH_BZ_;4;/Q.RR66O7!_>[TX,4Q))P-RX.<#.?XCMZ[X=_"/6?`'B/7=9 M3Q19WS:[U==XR\&:/X]T"?1-;M1/:R\C!PT; M#HZGLP]?PZ'%:RKQ4N5N\6DG\DOU.:&$DX<\5RS4FU?;5O>S[.WET-.^MS=V M,]N&VF6-D!],C%>3_LDZG!>_".*UC8>99WLT4@SR"3O'Z,/RKK/A[X)\3^"+ M&+3+SQA'K>GPX6%;C3BLT:#HHD$O(Z=5.,50N?A#/I'BVX\2>"=?'AV>_.=2 MM7LA_;)S$73C&5.^]K/7H:SC6G.G64;-736G6VSO;2W MW'>W5S#96LMS<2+'#"ADD<]%4#)/Y5PW[/>DSZ+\&_#EK<*5=K=I\$8XDD:1 M?T<5)K?PUU;QL\5MXO\`$L=WI,;!WT[3K)K..X((($K&61F48^Z"M=S6;:C3 MY$[W=_NO_F;QC*=95&K))KUO;MVM_77#\2>%_#WQ&\._8=5M8-0T^X4/&X/( MR.'1AR#[BO./@!HFK_#WQ5XH^']]J3ZE8Z>EO=64I7:J"0,6`7)VY..,XRI/ M>NA\&_#?Q?X$T^72]+\;V=UIV]FMHM0T=I6MP23M#+.F1D]Q],5M^!/A_!X+ M;4;V74+G5-7U619=0OY\*TQ4$*`HX55!(`'3-:<\80E!2NF<_LI5:E.I*%I+ M=Z;6VWUOT['3T445RGHA1110`4444`%%%%`!1110`4444`> MU6ZMO$QAC46;CR41Y51F&_Y@4V'(Q][WKH-/\63WUAX?N)FAL9M2MDF>![>2 M0EB%WQ@@C:5W8^;ZX^4UTU%:J:Y;6.=T9K0>*5T[35L[B$16QSDQMC>18L`L-I=54\YR2,>A[BBCF787LY6W_K^O MZ1P5AXNGL+2"!+.STV&XO]0C:Z2R=H4=+@^7N12#F529-V[!(_VACIM'U:\O M];U6VE6U^R6S1BW,;'S,D$.)%/3D9!'!!!S6O10Y*UK#C"2=V_Z_K4__V0`` M``````````````````#_P``1"``W`,@#`2(``A$!`Q$!_]L`A``%`P,$`P,% M!`0$!04%!@<-"`<'!P<0"PP)#1,0%!,2$!(2%1<>&146'!82$AHC&AP?("$B M(109)2(2$@`04%!0<&!P\("`\@%1(5%2`@("`@("`@("`@("`@("`@ M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("#_Q`&B```!!0$!`0$! M`0```````````0(#!`4&!P@)"@L0``(!`P,"!`,%!00$```!?0$"`P`$$042 M(3%!!A-180'EZ@X2%AH>(B8J2 MDY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ\?+S]/7V]_CY^@$``P$!`0$!`0$!`0````````$"`P0%!@<( M"0H+$0`"`0($!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&A ML<$)(S-2\!5B7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H MJ:JRL[2UMK>XN;K"P\3%QL?(RKR\_3U]O?X M^?K_V@`,`P$``A$#$0`_`/L6^OK;3+*:\O)X[>W@0O+)(V%10.237CVL?M%7 M&HW+P^$],B>!3A;F[#?O/<(",#ZG\!67^V#XRN-+T;1_#=O(R)J$CSW.#CW:I]BS9_P"`BO%_#/BM-/A`W`$#%>O@MG]ISQ+X>O%_MC2-/O;7.'$`:*0#V))'X8_&O:O`OCW1/B)H2:OH=SYD1 M.R2-AB2%^ZL.Q_0]LU\6>)==.KSI!`CRRRL%1(U+,['H`!R2:]2_9RT#Q'\/ M?'L<>L7%M8Q:I$89M-:4O-G!:-F5050@\88AL,>*TQV&P]*CS-J+_/R.;+,U MQ$L1RM\T._;YGT_17*:Y\4=%\.^)_P"P;^.Z600+,9D0-&`Q(P<'.>/2NDL; M^UU.U2ZLYTGA<95T.0:\%3BWRIZH^MC4A)N*>J)ZQ=9\=^&/#MS]FU?Q!IFG MS?W+FY6,],]R.Q%;5>/?M>1(_P`)0S*"4U&$J<=#AA_(FMZ,%.HH/J[&>)J2 MI495(]$W]QZCHGB71_$D+3:/J=I?Q)C+V\H=1G..1QV/Y5H5SWPSC2'X<>&4 M10JC2;8``?\`3):Z&BK%0FXKHQX>HZE*,WU285FZ]XIT3PM;"YUO5K+3HCPK M7,RIN]AD\GV%VUY;/\` M=E@E$B-]".*DNK2WO;=[>Z@BGA<;7CD0,K#T(/!KY_\`BYX3OO@/J<'Q`^'[ MM9Z=).L>IZ8"?LYST.WH%/3_`&21C&>+I4Z=67(M'T[&=>M6P\?:22E%;VT: M7?=W_`]^O]0M=+M6NKV>.W@3&Z1S@#M7.M\7?`"#GQIH`]OM\>?RS6EX-\4V M?C;POI^OV&1;WL(D53U0]&4^X((_"O&/@79VY^/'Q(4P1D)=2;05'RYG;.*5 M.BGS*>\5_P``*^)E%4Y4[-2:7WINY[)HWCWPKXBG%OI'B32+Z8](K>\1W_[Y M!S6U7F'QZ^&.@^(/`>JZQ'86]IJVF6SWEO>0((Y`8QO*EAU!`(YZ$Y%7OV>_ M%^H>-?A9INH:K(TUY$SVTDS=9=C8#'U.,9/<@TG2BZ?M(/9ZH<:\XUE1J+=7 M37ENK'2:I\0_"6AW36FJ>)-)L9UX,=Q=)&>/8D5HZ1K>FZ_9B\TJ^M[VW)P) M8'#J>,\$?45XA^VE&A\&:'(5&]=1*@XY`,9R/T'Y5[?H<:PZ+8QHH55MHU4# MH!M%$J<514UNW^00KSEB94G:R2?WDU[?6VFVKW5W.D$$>-SN<5CZ;\1?" M.LWB66G>)=)O+ESA88+M'?TZ`YK>KQKX(6T4?QA^*;)&H(OX<$#IEIB?S-33 MA&49-]%^J7ZFE:I.$H*-M7;\&_T/920HR2`!7'WWQH\`Z;-)#/XHL"8SM=HB M9%4^A900/SKF?VJ-8U#2/A1+]A>6..ZO(K>[:(X80G<6&>V2%7\<=Z[[PQ@TGRWUU\MM M.VOR+&@>)-(\5:>+_1-1MM0M=Q3S8)`RAAC(..AY'%:%8_A7PE8>$(;ZWTV- M(;:[O'NQ"B!5C+!<@`=L@G\<=JV*SGRW]W8VI<[C[^Y\\_MH>%KFZTK1/$<$ M;-#9N]M<$#[H?!0^PRK#ZD5\R"Z>%2=W`%?HMK.C6'B'2KG2]3M8[JSN8S'- M$XX8'_/7M7R_\1/V-]>MYII?!M_;7UHYREO=2>7+'[;L;6^OR_2O8R_'0IT_ M9STML?-9UE-2M5]M25[[HF^%/A)/AW\,5^(=_"K^(-9_=:277/V.%@?G4?WF M4$Y]"H[G.Q\'=.DU'QQ'J5Q)BWL$>[NIY&X7@X))]SG\#7*7FTH]%L75IPPCA3MI%)V[O\`K\/N.HDU*/QIXMU37SQ! M<2".VW#'[I!M4X]\9_&NH\!Z\WA[Q'#8^9FTO'$3)G@.>%8?C@?C[5YIIFKK M;1*JD*`,8K6\.7DNK^*]*M8XZ=>WO+XKW/I& MO(/VN?\`DD3?]A"'_P!FKU^O'?VO)%3X2A2<;]1A4?DQ_I7U.%_C0_Q+\SV\ M=_NM3_"_R/0_AO\`\D\\-_\`8)MO_12UOUS7PJNXKWX9>&)HG#*=)MP2#T(C M4$?@01^%=+2Q&E67JQX+7#4_\*_(^<_VMKIH?&?@<71Q8QR/(V>F?,CW?H!7 MT8.E>2?''P7#\:?!U]%H&)M5\/WK)"XMKCY'GV\;U!ZGCYAU!SQC%=,XNIAHI;QO?T>MSAI3C M2QLW)Z32L_..C7J>J5P_Q[@AN/@]XE2<`H+,N,_WE8%?U`KN*\>^.FO7'CM% M^%_A$K>:G?2H=3EC.8[&!6#$R,.A)`XZX!&.1GFH1))?#GQW^(3QZ'JVJK->2J MPL(ED,6)FY8%AQ],U[WX/\,6?@OPQI^@6&?L]E`(E8C!<]V/N3DGZUXO\!YT M?X^?$A58$MDP7/ANZU%/],N=7C\IC%U*1("=S,/4@8!'N/5_!7A#3_`?A>Q\/Z6K M"VM(]H9OO.Q.68^Y))_&N2^./PC7XD:+%>Z6_P!D\1Z;^]T^Y5MA)!SY9;L" M>0>QY])1]A\5Z?F*>&4;#<;>"P'9ACYE_$<=,Y+VE#] MWTW7Z^GY&L).CBOW^KDK1?3T]?S_``.:_;1_Y$C1/^PE_P"TVKV_1_\`D$6? M_7!/_017G'[3O@F\\9_#"7^SH6GN]-N%O4B099U`97`'<[6)Q_LUM_!3Q]I_ MC[P#IMS;7"->6UND%[#GYHY%7!)'H<9!]#[&I:YL*FNDOS-(M0Q[3^U!6^3= MT=M7C_P2_P"2N?%4CI_:%N/UFKU'7]?TWPOI%QJVK7<5I9VZ%Y)'.!]!ZD]` M!R:\]_9[T2^&FZ]XPU.V>UN/$VI/>Q0N,,D&3Y>?^^F_#%9TE:G-^5OQ7^1K M7:=:G%;W;^5FOS:/0?$?A[3O%>AW>C:M;K<65W'Y7,D;_=7/&'`_U;]@XX/&?2OHC5O%=IHWB;1]$N6CC; M54G\AF;&7C"':!W)#$_A5[6HM.FT>[CU98#I[0L+D3XV>7CYMV>V,U5&M*CH MU>+Z$XG#4\2[Q=IQV:Z?\`S_``/XTTKX@>&K77M'D+6TXP588:)A]Y&'8@_X MC@UMUXU^R5HUQIG@74[K;*NGWNJ226`D&"T855W_`(XQ_P`!KV6IQ-.-.JXQ MV+P-:=;#QG/=_P!7^>X4445@=92US1;3Q%I-QIE]'OM[A-K`=1Z$>X."/I7S MOXO^%'B#PK=/LM);ZRS\EQ`A88_V@.5/Z>]?2M%C45A0RZ%*7,W=G/A\MITI/Q&GB*RGOHHF#)";V9 M(PV"-VQ7"YP2,XSS7245Z,9.+NCT)PC-'M;D7W(R? M"7@_1O`VB1Z-H-F+2RC9F5-[.5CTP&'%=/X<\*Z+X1L!8Z'IEK86^YC9]S#(9O,YRV.O4XKN:\ZUK6+_6OA[KLU]&-=W MS'.0JGM3I.5^6+MB*`J@#.!QS7+>*/A+X-\8ZG'JFKZ)%) M?QX*W4,KP2\="6C92<=L]*K7'CF_TS1]:EO!8O<:=JT6GB8*T<($@A(D<$L5 M"B;GG^'MGB6_\0^((+30X8IM$6]U'49;-I45YH54132*P`93G]TH(SW/--1G M3M).W]?\$EU*-9.#5_*WFU^:9T.DZ-;Z+;F"VEO)$..;F[EN&_[ZD8FN7U?X M)^#M4U9]8@LKC2=2N=A`R?7&:MS^-)8O'%KH4&]AOM174==N8#NA?5 M[^6[$9]0KDKGWQ79@`#`KC=%\9ZIK-GJ%_'_`&2+>*"X,4*R,T\6I&,'#=>AHFIM7D] MATG1B[05K_I_PYH^-_AWX;^(5M;6_B"Q^T&V&T@CM[>*.&&-0B1HH554#```Z"G MUA>"=?O/$&ERRZC$L%[!-Y-Q`L>WRGV*Q7.Y@P^8$,#@@CH.35BBC85DR!=/M%25%M8`LW^M`C&'^OK^-`TZS$<,8M(-D'^J7RQ MB/\`W1V_"IZ*+A9$#:=9O'%O"&@E MFNKN:Y>58`C?O'+[2*.27!D=4`+XZ9 M/>F6NF6-D=UK9V\!V[,YQP.F23^-6**5QV17CTRQBCBCCL[=4A.8E6( M`(>N0, GRAPHIC 18 image_004.jpg GRAPHIC begin 644 image_004.jpg M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX. M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_ MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T] M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`##`L\#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH MHH`**CGGBMHFEGD2.->2SG`%Z8?Q?=3\SR?RJHPE+9&-]>MSSY]![U+XBUV#P_I,EW-A MG^[%'GEV[#_&O&KJ_N-4OY+N\D,DTAR3V'H!Z`5T4*/M'=['#C,7[%RN%GM97AF0 M_*Z'!%>E>$?B"FI.EAJY2*[;B.8<)*?0^C?H:\Q>H'I5:49K4,-B)TGIL?1U M%<+\//%[:I#_`&7J$FZ\B7,4C'F5!Z^X_4?C7=5Y>^:\ M^\6^'[WPI>Q*M]/+;3@F*3>5.1U!YZ\BMH4XS=DSFJUITES..GJ>V45\Z_VA M>$8^V7./^NS?XUW'A'P.VN:8FHZG?W:Q2D^7'')@D`XR2<]Q5SPZ@KR9G3QC MJRY8Q_$]1I:QM#\+6/A^262S>Y9I5"MYLQ<8'MTK9KG=KZ'9%MK4****0PHH MHH`****`"BBDH`6DK)UWQ/IOAZ'=?3_O6&4A3EV_#M]37G6J_$O6-3E\C2HA M:(YPH1?,E;\?\!6L*,I[&%7$4Z>C>IZS)(D2%Y'5%'4L<"LV?Q1HEL<3:K9J M1V$H)_2O-+?P-XGU]A-J,C1!N=UY*6;_`+YYQ^E;-O\`"*(*/M.JN3W$4(`_ M4FJ]G3C\4C/VU:7PP^\ZG_A-_#O_`$%K?]?\*L0>*M#N#B+5K,D]C*!_.N6/ MPET\KQJ-V#ZE5_PK/O/A).JDV.IQR'^[-&5_49_E34:+^T)U,2OLH]+BGBN$ MW0RI(OJC`C]*?7A.H>'==\,OYLT,\"`\3P.2O_?2]/QQ5[2OB+KFG%1-,M[$ M/X9QS_WT.?SS3>&;5XNY*QJ3M4C8]IHKF/#_`(]TO766%F-I=MP(I3PQ_P!E MNA_G735A*+B[,[(3C-7B[BT445)044R6,2Q/&V=KJ5.#@X/O7(S_``STJ1#Y M-UJ$+]F$^['X&JBD]V1-R7PJYV-)7A/B+3=0\,ZN]E)>S.NT/'(KL-ZGVSP> M#631?#7Q',`9KV" M,GLT[L?T%/?X7Z\HRFHVS'T\V0?TJ/90_G-O;U/^?;/5J2O&;KPCXMTH%XQ< MR*/XK:X+'\LY_2J5MXR\1:;*5_M&X+(<&.X&_'L0W-4L/S?#),AXWE?OQ:/= M**\XT/XJJ[K#K=L(P>//@R0/JO7\ORKT*WN(KN!)[>198I!N5T.016,Z'K$ZAI]_,CCJ8QTY*>#]`NO%5_*DU]<1VT"AI'#DL2>@&?H:],T3P=I^A M7?VFUENWEVE5(4.>G;KUKD]5^&47V9WTC4+R.=1E4EEW*Q],\$?6KBHO= MV,YRG'X8W^9WM%?.IO;V,E/M5RI4X(\UN#^==5X,\+3^*1-@&1^=;2P_*KMG+#&NI+EC'7U/8**QM"\+V/A]Y7LWN6:4`-YLQ?I[ M=*V:YW:^AVQ;:U"BBDI#%J.:>*WC+SRI$@_B=@H_,UY]XK^))MYI++0BC.IV MO=,,@'T0=_J>*Y[3/">O^,"+V[G=8'Y$]TQ.[_=7T_(5O&AIS3=DR2J3_.K= M>!ZYX8U+P]*OV^#",<)-&=R-^/8^QKM?A(TLAU1GDD95\M0&8D#[U$Z"4>:+ MN*EBI2G[.4;,](HHHKG.T***R_$NI'2?#M]>*!^I%-*[L*344VS MRWQUKQUGQ#)'&^;6T)BC`/!/\3?B>/H*P8S@BJJGU.3ZU,C5Z$J,4D?,5IN M4#O3;)@F3V=Y-I]Y#=VS;)H7# MH?<5[_H^IQ:QI-M?0$.@;']T]Q^!R*\,TSPSK6L@-8Z=,\9Z2.-B?F<9_"O M5O`6DWVA:9-8:C-;,XD\Q(XI-Q0$<@\>H_G7%B7%K?4];`J<6TUHSJJ**SM9 MUJVT*T6YO!(8V<1CRUR??%M,Z7IS]Q M.P_-?_K5Z#7`_%H?\26Q/_3S_P"RFM:'\1'/BOX,CRNO>?""!/".EC_IW0_F M,UX-7OGA88\*Z7C_`)]8_P#T$5TXOX4<.7_&S6HHHKA/6"BBB@`HHHH`**** M`"N*\:^.TT3=8::5DOR/G<\K#]?5O;\ZO^-_%`\.:5B`@WUQE80?X?5C]/YU MXS%%/J%ZD4>Z:YN),#)R68GN?K730H\WO2V.'%XEP]R&YI:/H^H^+=7=4=I) M&.^>XE)(0>I/\A7L'A_PKIWAV`"TB#3D?/<.,NWX]A["I/#>@0>'=(CLX0#) M]Z:3'+OW/^'M6M4U:SF[+8TP^&5- M*_AQ!>(]YH:+!*5&21 M#M96&"I'8UW7@[XA2V+QV&M2-+:GY4N&Y:+_`'O5??J*V?B/X36\M7UBRCQ< MPKF=5'^L0=_J/Y?2O*J]!.->&IY$E/"U-'_P3Z15E=0RD,I&00>"*6O-OAGX MI9B-#O'S@$VK,>PZI_4?C[5Z37!4@X2LSUJ5558\R"BBBH-3ROXM+C6-/?N8 M&'Y-_P#7KBM._P"0I9_]=X__`$(5V_Q;_P"0EIO_`%Q?^8KB--_Y"EG_`-=X M_P#T(5Z5'^$CP\3_`!V?1-%%%>:>X%8?B/PI8>([8BXC$=R!^[N$'S*??U'L M:W**:;B[HF45)6D?/&J:;<:/J4UE=KMFB.#CHP[$>QKH_`/BJ31=32QN9";" MY;:03Q$YZ,/0'O\`G6[\6=,7R;+4D7#AC!(?4$97^1_.O-*]*+5:GJ>+-/#U MO=/I&EK*\,7[:GX:T^[2$;SZL.#^HK5KS6K.Q[<7S),****0S`\])3< M#RJ#[WYY`_&NQKR?XL2,?$%G&?NK;9'U+'/\A6M"*E-)G/BYN%)M&)X)T2/7 M?$D%O.NZWB4S2K_>`Z#\217N*J%4*H`4#``[5Y'\++E(?%$L3D!I[=E3W((. M/R!_*O7JTQ+?/8RP"2IW04445S':5=1T^#5+":SND#Q3*5((Z>X]Q7$_"NW: MT_MJ"3[\4ZQM]1N%>@53LM+M-.FNI;6$1O=2>;,02=S>M6IVBX]S*5.\XS[% MRBBBH-0KC?BE.8O"8C!_UMPBGZ#)_I795Q'Q60MX9MV'1;I<_P#?+5I1^-&& M)_A2/)0<5*K5#2@XKU3Y]JY:5ZG28BJ2M3P],SLUL7Q M4GJ:JRS@=ZCFN,#K75^!_`F@_(G1IS_1??OVK*I54$;T,/*I( MR?#WA;5/%,W^B)Y=JIP]S)]P>P_O'V'Z5Z-:>%O#G@RW2XNT^UWG\+S`,S'_ M`&5Z#Z_K6[JVIVOAO3$C@B16"[(($&!^78"O/+N[GOKE[BYD,DK]2?Y#T%>1 MB<9+9'JL?\`Z"*Z<7\*.++_`(F:M%%%<)ZH4444`%%%%`!2,P52 MS$``9)/:EKG?'>HG3?"-ZZ'$DH$*$>K<'],TXKF:1,YA6]RE9'CX9.K7YI>IW%%%%><>T%%%%`!1110`4444`(P#*0P! M!X(/>O!O%FC?V%XCNK1!B'/F0_[C<@?AR/PKWJO-OBW8C&G7ZCG+0L?_`!X? M^S5T8:5IV[G'CJ?-3YNQYW;7,MG=17-NQ66%PZ,.Q!R*^@M*U"/5=*MKV+[D M\8?'IGJ/P-?/%>O_``NO3<>%F@8Y-M.R#Z'##^9K?%1O%2.7+YVFX]SLZ*** MX#UCRWXM_P#(2TW_`*XO_,5Q&F_\A2S_`.N\?_H0KM_BW_R$M-_ZXO\`S%<1 MIW_(4L_^N\?_`*$*]*C_``D>)B?X[^1]$T445YI[84444`<=\4-O_"(G/7[1 M'CZ\_P#UZ\>KT7XKZNLDMII4;9,?[^7'8D84?ED_E7`6EI-?7D-K;KNFF<(@ M]S7HX=6IZGBXQ\U:R/:?A^K)X)T[=W5R/IO:NCJKIMDFFZ9;6<7W((UC!]<# MK5JN"3O)L]>G'EBHA1114EF'XS_Y$[5/^N#5X37NWC/_`)$_5/\`K@U>$UW8 M3X6>3F'QKT/4OA)_R"M1_P"NZ_\`H(KT"O/_`(2?\@K4?^NZ_P#H(KT"N:O_ M`!&=V%_@Q"BBBLCH"BBB@`HHHH`^?O$/_(R:G_U]2?\`H1KU/X9?\B=%_P!= MI/YUY9XA_P"1DU/_`*^I/_0C7JGPS_Y$V'_KK)_Z%7=B/X2/)P?\=_,ZVBBB MN$]8*\T^+5@V_3]0493#0.?0_>7_`-FKTNL_7-(AUW2)["XX65?E;NC#H?P- M:4I\DDS&O3]I3<3P.SNYK"\ANK5RDT+!T;T(KW#PMXHM?$U@)(R([E`/.@)Y M4^H]0?6O$]2TVYTG4)K*\C*31'!'8CL1[&FV%_1W5E,T,\9^5E_D?4>U M=U6DJJNCR:%>5"5GL?15%A1EH0)A_P$Y/Z9KI*9-$D\+Q2 M#Y\X45=UG2Y-&U>YL)0_M7N+M!I]F6(6*"!.@&`J@=`*S_"^@Q>' M-!M["/!=1NF=.T6%'7$LG[QQZ$]OP&*VP\;SOV-L/&\[]C6)`!).` M.YKR+5+W^V?$-S=@YC9]L?\`NC@?X_C7;>.=<_L[2OL<+8N;L%1CJJ?Q'^E< M1I=OC!Q6M>5WRE8J?-)4UT-BUBVQ@5;6/-1Q#``JX@&*S2'%%9H\5!(E7I`* MJR4F@:.C\,ZD;B`VDK9DA'RD]U_^M6[7GME=FQU"&X!X5OF]U/6O0000".AK MJHRYHV.FC+F5A:***U-0HHHH`*X+XM?\@2Q_Z^?_`&4UWM<%\6O^0)8_]?/_ M`+*:UH_Q$<^*_@R/*J]]\+?\BMI?_7K'_P"@BO`J]]\+?\BMI?\`UZQ_^@BN MG%_"CBR_XF:M%%%<)ZH4444`%%%%`!7`_%J8KHUA"#P]P6/X*?\`&N^KS_XM MQDZ5I\G99V4_BO\`]:M:'\1'/BOX,CRVO9?AF`/!L&.\LF?^^J\:KU[X63B3 MPJ\>>8KEP1]0#_6NO%?`>=@'^]^1VE%%%>>>R%%%%`!1110`4444`%AXS7IOPB8_9- M47L)(S^A_P`*\RKU'X20E=+U&8CAYU4'Z+_]>N[$_P`-GE8+^,CT&BBBO-/; M/+?BW_R$M-_ZXO\`S%<1IO\`R%+/_KO'_P"A"NW^+?\`R$M-_P"N+_S%<`C, MCJR$AE(((Z@UZ='^$CP\4[5VSZ0I:\=L_B1XBM%"S+%<@<9EA(/YC%7U^+.H M@?/I=N3[,PKC>'F>BL;2>YZG6)XG\3VOAK3S+*0]PX(AASRY_H!W->?W?Q5U M>9"MM;6ML3_%@N1^?'Z5S5LS>(-=C&K:B8VG;:US*-VWT'L/T%7##/>>QG4Q ML7[M/#]+\.J'MHS+@^E;U*K7YERQV'A\)R/GGJPHHHKF.X M****`,/QG_R)^J?]<&KPFO=O&?\`R)^J?]<&KPFN["?"SRAZE\)/^05 MJ/\`UW7_`-!%>@5Y_P#"3_D%:C_UW7_T$5Z!7-7_`(C.["_P8A11161T!111 M0`4444`?/WB'_D9-3_Z^I/\`T(UZI\,_^1-A_P"NLG_H5>5^(?\`D9-3_P"O MJ3_T(UZI\,_^1-A_ZZR?^A5W8C^$CR<'_'?S.MHHHKA/6"BBB@#G_%?A.U\3 M68#$17<8/DS@=/8^HKQG5-)O-&O6M+^$Q2KT]&'J#W%?0U9VLZ'8Z]9&VU"$ M.O56'#(?53VK>C7<-'L&Y#*SP3QW,"30NK MQ2*&5E.00>AKSZM)TW8]BA7C6C=;DE%%%9FX4444`<+\2?##:E9+JMG&6N;9 M<2JHY>/K^8_EFO)Z^D:\O\<>`7MY)=3T:(M`V6FMT'*'NRCT]NW\NS#UK>Y( M\W&89O\`>0^9Y]11UHKM/+(Y6P*ZCX6Z0-2\6BYD7,5BAEY_OGA?ZG\*Y.'[R\(^:XN-N?90/ZDURUY61W8.%YH]!KSOQE.9O$$B9XA14'\S_. MO1:\O\1DGQ%?9_YZ?T%>1B7[IWXI^X9M%%:>B:%<:W/\@,=LI^>8C]!ZFN*, M7)V1PQBY.R+7A713J=^+B9?]%MVR<]';L/ZFNWU?5K;1=/DN[IL*O"J.KMV` M]ZJ7^IZ9X3TI%9:KK%YXCO\`S[H[8UXBA4_+&/ZGU-=B M:HQMU.F=6.'CRQUDPN+RXUO4Y+VZ^_(>%'1%[*/I6M:H(U%4;6(1@5>1JYKW M=SGIJVKW+T;5.LG%44>I!)5)FZ99:3-02-33)43O0V#8R0YS7?Z+.;G1[60] M3&`?PX_I7GCM7<^%B3H$&?5O_0C6M!^\:4'[S-BBBBNLZPHHHH`*X+XM?\@2 MQ_Z^?_937>UP7Q:_Y`EC_P!?/_LIK6A_$1SXK^#(\JKWWPM_R*VE_P#7K'_Z M"*\"KWOPH=WA32S_`-.L?_H-=.+^%'%E_P`3->BBBN$]4****`"BBB@`KE?B M/8F\\'W#*,M;NLP^@.#^A-=545S;QW=K+;S#='*A1AZ@C!JHRY9)D5(\\7'N M?.5>A?"74`E[?V#''FHLR#W'!_F/RKB-5TZ72-4N;&<'?`Y7/J.Q_$8-2Z#J MK:)K=K?KDB)_G`_B0\,/R->E4CSP:1X=&?LJJ;/H*BHX)H[B".:%@\6>^%%%%`!1110`4444`%<-\5[D1^'K:WS\TUP#^"@G^HKN:\C^*.J M"[\0164;92SCPW^^W)_3;6U"-ZB.;%SY:3\SB:]M^'^GG3_!]H'&'GS.P/\` MM'C],5Y)X>T=]=UNVL4!VR-F1A_"@^\?R_F*]^CC6*-8XU"HH"J!V`K?%3T4 M3DR^GJYCJ***XCU#RWXM_P#(2TW_`*XO_,5Q&G?\A2S_`.N\?_H0KM_BW_R$ MM-_ZXO\`S%<1IO\`R%+/_KO'_P"A"O2H_P`)'B8G^._D?1&`>PI"BGJJ_E3J M*\T]LY+QOX/CUZQ-Q9QJNH0#*8&/-7^Z?Z5XVRE&9'4JRG#*PP0>X-?2-><_ M$;P?YH?6M.C^=1FZC4?>']\>_K^==>'K6]V1Y^,PW,O:1W%^'GC/SQ'HVIR_ MO0-MM*Q^^/[A/KZ>O2O1:^;@Q4AE)!!R"#R#7KW@/QD-;MQ87[@:A$O#'_EL MH[_4=_SHQ%&WO1%@\3S?NY[G9T445R'HA1110!C>+T,GA'5%'7[,Y_(9KP:O MHG4;;[9IMU;8_P!="\?Y@BOG;:5^5A@C@BN["/1H\K,5[T6>H?"-P=/U).XF M0_FO_P!:O0J\M^$MV$U+4+4G_61+(!_NG!_]"KU*N?$*U1G9@W>B@HHHK$Z0 MHHHH`***ANIUM;6:=_NQ(SGZ`9H`\`UJ3S==U!QT:YD/_CQKU[X=Q>5X*LL_ MQEV_-S7BLDAD=Y&ZN2Q^IYKW[PY9G3_#FGVQ&&C@0,/?&3^IKNQ+M!(\K`J] M24C3HHHKA/5"BBB@`HHHH`9)$DT;1RHKHPPRL,@CT(KRKQMX".E+)J.DH6LQ MS+#U,/N/5?Y?3IZQ2,H92K`$$8(/>M*=1P=T8UJ,:L;,^;J],^%>O-(D^CSM MGRQYL&3T7/S+^9!_$UR?C;0ET#Q%+#`NVVF'G0C^Z#U7\"#^&*/`D[6_C/3B MO\;M&?H5-=U2U2G<\FBY4:Z3[V/%><--S MEJX2G4UV9\QSG#$'@CM7N'PQC$?@2R(_C:1C_P!]G_"M^\T33=1R;W3[6I^@IFI^/XH(?LN@6P"J-JRR+A5'^ MRO\`C7)-;M+(7E=G<]68DG\ZD2!5[5R^U45:"L<'M96M!6_,@E^T7]RUQ>2O M-,W5W.3_`/J]JL1Q!*D``HK%MLS44M25&J=7JH#BGJ]"9HF75>G>950/3O,J MKEE<*/Q MKU:*-8HDC085%"@>PKHPRNVSHPRNVQ]%%%=9V!1110`5P'Q;/_$HT\>MP?\` MT$UW]>=?%V0"TTN//)DD;'T`']:UH?Q$<^*_@R/,J]W\&/O\'Z6?^F"C\N*\ M(KV;X;7JW7@^",,"]L[Q,/3G(_0BNK%+W4<&7NU1KR.LHHHK@/7"BBB@`HHH MH`0D*"20`.234%E?6VHVJW-G,DT+YVNAR#@X-8GCC7(]%\.7'S`7%RIAA7N2 M1@G\!S^5'@"W^S^"M/'0NK/^;$_RJ^3W.8R]I^\Y%V,3XE^&&OK8:O9H3/;K MB=5'+1^OU'\OI7E=?2)&1@\BO*_&_@*2QDDU+1XB]JY(XL9AFW[2'S+7PV\6K&%T2^DP,_P"BNQ_\<_P_+TKTNOFT'&"#@CD$ M5Z3X2^)"A$LM?<@CY4N_7V?_`!_/UHKT'?FB&$Q2MR3/2:*9'*DT:R1.KHPR MK*<@CV-/KC/2"BBB@`HHK+USQ#I_A^U,U_,%8CY(EY=S[#^O2FDV[(3DHJ[# MQ#KD'A_2);V<@E1MC3/+N>@_SVKP:YN)KV[EN)V+S3.78^K$UJ^(O$5[XJU- M9)%8(#MM[=,G;G^;'UKNO!'@'^SFCU+6$!NA\T,!Y$7N?]K^7UZ=L$J$;RW/ M+J.6+JY_^M77445QRDY.[/2IP4(J, M0HHHJ2SRSXMG_B:ZQ.-0M3Z3)_P"A"NS^+$@;Q!9Q@\I;9/XL M?\*X>)_+FC?^ZP/Y&O3H_P`-'AXE_OV?2%%-5@Z*PZ$9%.KS#W`I"`1@C(I: M*`/(/'W@[^Q;DZA8)_H$S?,H'^I8]O\`=/;TZ>E&K_*!I+"4_N9#V_V6]Q^M=U" MMS+EEN>3B\-R/VD-CTGP;XOB\26?ES%8]0A'[V,='']Y?;^5=/7SI9WD^GW< M5U:2M%/$=RNO;_ZWM7LWA'QC;>)+81N5AU!!^\AS][_:7U'\JRKT.7WH['3A M<4JBY9;_`)G2T445S':%>%^-=).C^*+N(+B*9O/B]-K<_H5^%=7&A^([2\D>`?'$:PQ:1JT MH0IA;>=SP1V1CV]C^%=&)IN7O(Y,%74'[.1Z1124M<)ZH4444`%BV+75_,L<:]!_$Q]`.YKQ/Q%KMUXIUHS MF-L$^7;P+R5&>![D]ZWH4W*5WLCDQ=90ARK=AX4TAM;\1VEKMS$&\R7V1>3^ M?`_&O>:Y;P+X5_X1W33+=`?;[D`R=]@[*/Z^_P!*ZJBO4YY:;(>$HNE#7=A1 M116!U!7->"==N=>L;Z:[=&:*[>-`JXPF`0/UKH9VV6\C?W5)_2O)OAIXACTW M59K*Z<)%>X*,>@D'0?B#CZ@5K"'-"3.>K5Y*D$]G<]=HI*6LCH"BBFNZQHSN MP55&2Q.`!ZT`>9_%T)]KTL\;]DF?IE:Y_P"']HUWXRLB!\L.Z5CZ``C^9%1^ M-M?7Q!X@DF@.;6%?*A/]X#JWXG],5W7PT\.OIFFOJ-TA6XO`-BDWE;=#^]D_H/>FDY.R'%.3LC9\$Z26D?4I5^492'/<] MS_3\Z[2HX(8[>%(H5"1H`JJ.PJ2O2IPY(V/4IPY(V"BBBK+"BBB@#(U3Q3H^ MC3^1J%]'#-M#>602V#TX`KRGQUXF@\1ZO&]H6^RVZ;$+#!8DY)QV[?E7LL]A M:73A[BU@E8#`,D88X_&F+I=@GW;*V'TB7_"MJ=2,'>VIS5Z4ZJY;V1\[[AZB MM#1]?O\`0;@S:=?]`VV_[^G_``KT@Z58'K8V MI^L2_P"%-.C::>NGVA_[8K_A6?M*7\IM[&NOM_@><'XN7W;3;;_OXU,;XM:F M?NV%F/J6/]:](.A:4>NF67_?A/\`"FGP]HYZZ78_]^%_PH]I2_E#V-?^<\RD M^*NMO]R&Q3Z(Q_\`9JH7'Q$\17`(^W+$#_SRB4?K@UZT?#6BGKI-C_WX7_"D M_P"$9T3_`*!-C_WX7_"J56DOLD/#UW]L\*GNKW5KM3//-=7,A"+O8L23T`KW M_3+0:?IEK:+T@B6/CV&*CMM%TVRD$EK86L+CHR1*"/QQ5ZLZU7GLDK&N'P[I M7Q]Q7G.K>#]:T8L;FR=XA_ MRUA^=/TY'XBO=Z*WAB)0TW.6K@Z=379GS_I'B/4]#?\`XE]X\:YR8C\R'ZJ> M*[&Q^+5PBA=0TZ.0_P!^%]OZ'/\`.N^O=`TK46MZA]`JG_V:H[CXLZ:@ M_P!'L;N4_P"UM0?S-7Q\,O#V?]5<'V\\U:@^'_ARWP?[.60_]-)&;^9J+T>S M-.7%=TNVSM((!_TSC"_RJU1[=1^!6#ZJYN]65SG_``[X-TSPX`\" M&:ZQ@W$O+?A_='TKH***PA:7<2P7>H(L\1P M\:JS,#Z<"MVJLNFV4\ADFL[>1SU9XE)/XXIQMU)ES6]T\.\5:XOB#Q!/>Q@K M"<)$K==HZ9^O)_&L?*GN*^B5TRQ3[ME;#Z1+_A3FT^T;[UK`?K&*ZUB5%62/ M/E@)2;DY'%^'?B5I1TNW@U25K>YB0(S;"RO@8R",UT^F>)M(UF=H=.OHIY57 M>47(..F>1[U9.D:>>MA:G_MBO^%2P6-K:L6M[:&%CP3'&%)_*N>3@]4CLA&I M&RDTR>BBBLS8*K7]A;:E9R6MY$LL$@PRM_G@U9HH!J^C/'O$?PYU#2Y7FTU' MO;/J`HS(@]"._P!1^5>,Y4\JRG^=?1U136L%Q_KH8Y/]]0?Y MUU1Q32M)7."I@(MW@['F6A?%6:W18=:@^T*.//BP'_%>A_#%=7;_`!$\-W"@ MG4!$?[LL;`_RQ6W_`&/IW_0/M/\`ORO^%']CZ=_T#[3_`+\K_A6!B0'3ID=:LTR*&.",1PQK&@Z*@P!^%/K$W5[:G M*^*_`MGXBSM>6ZQX7U;0V87MF_ECI*@W1G\1T_'%>^ M4A&1@\@UO3KRAINCFK82%5WV9XGH/C[5]$C6$2+=VR\".8D[1[-U'ZUUUM\6 MK!@/M6G7,;=_+97'ZXKJ+WPIHFH,6N=,MF8]65-I_,8K+D^&OAUSD6TR>RSM M_4U;J49:M&4:.(IZ1DFBF_Q6T8*2MM?,?38H_P#9JQ=2^+-Q(A73;%(<_P#+ M2=MQ'X#`_6NEC^&GAU#DV\S^S3M_2M2R\)Z'I[!K;3+=7'1F7>?S.:GFHK9- ME\F)EHY)'E%OI'B/QI>"XD6:8'_EO/\`+&H]O\`*](\+^!['PX!.Q^TWQ',S M#`3V4=OKUKI@,#`Z"EJ9UI25EHBZ6%C!\SU84445B=(4444`1SH9;>1%ZLI4 M?B*^>;_3KO2[@V]];R02+QAUQGZ'N/I7T545Q;07<1CN88YHSU610P_(UM1K M>SZ'-B,/[9+6UCR'0OB/JFD1)!=*M];KP/,;#J/0-W_&NJM_BOI+K^_M;R)O M0*K#\\UKW/@+P[=$EM-CC)[Q,R?H#BJ9^&7AXG_4W`]O/:K+Y/L5O"R0N?^/:V!8O_`+QZG]!7 MHEO\/?#EN<_V>)#_`--9&;],XK=M+&UL(O+L[>&!/[L:!1^E)5*<-8HIT:]3 M2N@HJ91 M4E9DRBI*S/);VQN=/G,5W"T;]L]#]#WJ"O7+BVANHC'<1)(AZJXR*P+OP1I\ MY+6[RVY/93N7\C_C7)+#-?"<<\*U\)P5%=5+X"N0?W5Y"P_VD(_QJ,>!+XGY MKJV`]MQ_I6?L9]C+V%3LNP[K&@7]3FMW3]!T_3<-;6 MZ^8/^6C?,WYFKCAYO?0N.&F]]#D-&\(W-\5EO0UO;]<'[[?AV_&NZM;6&RMT M@MXQ'&@X45-1753IQAL=E.E&GL%%%%:&@4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%% M%%`!16/XFUJ?0=)>]@L6NPGWP'"A!_>/?'TIOA+5Y]=\/PW]TL:22L_RQ@X` M#$#K]*KE?+S=".=O,_&=I=MXXT>W?4[DK<2!HR,#[.2^/E`'7W/-=II6A7 M.G79FFUJ_O5*E?*G*E?KP.M:2@E%.^YC"JY2<;;">,?^10U7_KW:J7PZ_P"1 M)LOK)_Z&U7?&'_(H:K_U[M_*N9\&:)=ZOX2MO/U6ZMK0%Q'#:$1D_,=:;<:EX7\>P:+/?SWMC=+E/.;<1D'!]B",>A MKT6HG#E-:=3G3TLT%%<3KOB=)O$3:.-0>PM+==US<1*6D=NR*0#MZ\FLC6]6 MM-)2&[\,:GJ$UTL@\R"4RR1R+WSO'\O6J5)LB6(BK^1Z;14%E<&[L8+@H4,L M:OL/5.9TD@A<8CC.['('WL8SS4PAS.Q=2IR1YK7 M/2**Y;3?#.L6?B8:A=:]+=VQ0AHF!7<2.FW.T`=>*T?$NIWNEZ7OTRQDO+N1 MA'&BJ2%)_B;';BDXZV3!3?*W)6-BBN(U_P`/WJ^')=2DUG41J4$/G-MFVQY` MR5"K@`=I`1^&+R>PO'M984,A9`"6`ZKGM]17.>#-(O=9\*1--J]W;VYDDVI;$*[' M<'/1 M@.01UKTR.198ED0Y5P&!]0:4XM4J M39$L1%7\CTZBH;6?[3:0S["GF(K[3U7(S@UP8FOK7XJ6VGOJ5W/:E3*LZFDFE>63<\C%B?F/T]_DL=/4%K>V][YWV:59/)D,4FW M^%QU'ZU1\1PW$NB7)M;V6T>.-I-\0&3A2<9(X^HYKB/`.AW6I^'WN(M:O[,& MX8&.!AM)P.>0>33C!.+DV3.HU-12/3*SI=`TR?5DU.6SC:]CQME.&,#KTZF ME"+;=F.K-12;5]3T2BDKE=3UB\U3Q+_PC^CS?9_*3S+R["AF01S[^ MU*,6RY343JZ*Y74?!;RVS/I^L:I#?*,I+)=.P8_[0_PKH;".XAT^WCO)!+<) M&JRN.C-CD_G0TK:,492;LT6:*X2*_P#^$A\H7L]O;6OR6]M%*8O-(ZD MD8)/?%;^AZ3>Z1J5Y&UW-@5SWBKPA#XF^SR_ M:7M;FWSLE09XZX(^HJWH^D7MBWF:AJ]Q?R;=BAE"(H]<#J?[52^'7_(DV7UD_P#0VK0U[1)M/5)];NS>Q8\MQ$@"`=`!C'-KHZR-UEC5XV#(PRK*<@CU% M'?^`?^AFN_1%C1410JJ,``8`%34M6CU*XUJZ^U0D&%E MC0",`Y``Q4TFD[LNO&4HI)'65C^)?$=MX9TS[7O8<5H64, M]O;!+JZ-U("(/[;OO"-[>7ES!90FW+_98$WLP(Z,Y_H!]:T/AVNWP38^Y<_\`C[5' M;>"Y7TPV&K:U>7ML$V)$N(U4=LXR6QQC)Q[5+X;\)W/A\B,ZQ<3VB,6CMQ&% M7)]3R3].!FM)./(XWZF$8S513:Z6W+GB_P#Y%'5?^O9_Y5G?#?\`Y$JU_P!^ M3_T,UH^+_P#D4=5_Z]G_`)5R7@+1]6;08[O3]:^S0S.VZ![<2*"#C(R>#Q1% M)TGKU";:KJROI^I8^*0-Y;Z5IT"[[JXN#L0=<8Q_-A7<6D/V:SA@SGRHU3/K M@8K,T[PY#::@VHW<\M]J++M^T38&P>B*.%%;-1*6BBNAK"#4G-]3SGPI?KI? MQ"URPO6"27";D*L6K:]?7]H/\`EV)*HX]&Y)(]JN;C/WKV9G352G>- MKKH=6CK(BNC!D895@<@CUKS^]8)\9[0L<`P@#/KL:O0%4(H50`H&``.`*YOQ M-X,BU^]@OH;N6RO80`LJ#.0#D>G(/?-33DDW$]4)(`^ MS/\`RK*^&G_(F6__`%UD_P#0C3KCP?=W^ES6^IZU'$51JEU.@);R<*L63U..OZU5XJ#CM,X[XI1:Y'%LN^AB\F!(@S MOL4+N=LL<=R>YKEKOP-)?:O'JD^MW1O(L>6ZQ(`@'0`8QW-*FTF[A7C*222Z MG6UYOH-\FD_%#6+:^;8;QR(V;@9)W*/Q!KT.VCDBMXTFF,TBKAI"H7)MDLQ>"Z0;5GCQG'H1W%%.25U+9CK0E*TH[HZ"H[>XANX5FMY$EB M;.'0Y!P<'GZBN4M/`]ZJ""_\2:A_T;5R9+FP(`D)R2,D$$]^G!]ZNVOA:^TFXN3H^LF"VN)#(8)K<2A& M/4J'H-#^T2B62XN[I]\]Q)CYGGNH62-886?GIR0,#KWK-^'UV]GHUOI5Y9WMO M GRAPHIC 19 image_005.jpg GRAPHIC begin 644 image_005.jpg M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX. M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_ MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T] M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`##`L\#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH MHH`**CGGBMHFEGD2.->2SG`%Z8?Q?=3\SR?RJHPE+9&-]>MSSY]![U+XBUV#P_I,EW-A MG^[%'GEV[#_&O&KJ_N-4OY+N\D,DTAR3V'H!Z`5T4*/M'=['#C,7[%RN%GM97AF0 M_*Z'!%>E>$?B"FI.EAJY2*[;B.8<)*?0^C?H:\Q>H'I5:49K4,-B)TGIL?1U M%<+\//%[:I#_`&7J$FZ\B7,4C'F5!Z^X_4?C7=5Y>^:\ M^\6^'[WPI>Q*M]/+;3@F*3>5.1U!YZ\BMH4XS=DSFJUITES..GJ>V45\Z_VA M>$8^V7./^NS?XUW'A'P.VN:8FHZG?W:Q2D^7'')@D`XR2<]Q5SPZ@KR9G3QC MJRY8Q_$]1I:QM#\+6/A^262S>Y9I5"MYLQ<8'MTK9KG=KZ'9%MK4****0PHH MHH`****`"BBDH`6DK)UWQ/IOAZ'=?3_O6&4A3EV_#M]37G6J_$O6-3E\C2HA M:(YPH1?,E;\?\!6L*,I[&%7$4Z>C>IZS)(D2%Y'5%'4L<"LV?Q1HEL<3:K9J M1V$H)_2O-+?P-XGU]A-J,C1!N=UY*6;_`+YYQ^E;-O\`"*(*/M.JN3W$4(`_ M4FJ]G3C\4C/VU:7PP^\ZG_A-_#O_`$%K?]?\*L0>*M#N#B+5K,D]C*!_.N6/ MPET\KQJ-V#ZE5_PK/O/A).JDV.IQR'^[-&5_49_E34:+^T)U,2OLH]+BGBN$ MW0RI(OJC`C]*?7A.H>'==\,OYLT,\"`\3P.2O_?2]/QQ5[2OB+KFG%1-,M[$ M/X9QS_WT.?SS3>&;5XNY*QJ3M4C8]IHKF/#_`(]TO766%F-I=MP(I3PQ_P!E MNA_G735A*+B[,[(3C-7B[BT445)044R6,2Q/&V=KJ5.#@X/O7(S_``STJ1#Y M-UJ$+]F$^['X&JBD]V1-R7PJYV-)7A/B+3=0\,ZN]E)>S.NT/'(KL-ZGVSP> M#631?#7Q',`9KV" M,GLT[L?T%/?X7Z\HRFHVS'T\V0?TJ/90_G-O;U/^?;/5J2O&;KPCXMTH%XQ< MR*/XK:X+'\LY_2J5MXR\1:;*5_M&X+(<&.X&_'L0W-4L/S?#),AXWE?OQ:/= M**\XT/XJJ[K#K=L(P>//@R0/JO7\ORKT*WN(KN!)[>198I!N5T.016,Z'K$ZAI]_,CCJ8QTY*>#]`NO%5_*DU]<1VT"AI'#DL2>@&?H:],T3P=I^A M7?VFUENWEVE5(4.>G;KUKD]5^&47V9WTC4+R.=1E4EEW*Q],\$?6KBHO= MV,YRG'X8W^9WM%?.IO;V,E/M5RI4X(\UN#^==5X,\+3^*1-@&1^=;2P_*KMG+#&NI+EC'7U/8**QM"\+V/A]Y7LWN6:4`-YLQ?I[ M=*V:YW:^AVQ;:U"BBDI#%J.:>*WC+SRI$@_B=@H_,UY]XK^))MYI++0BC.IV MO=,,@'T0=_J>*Y[3/">O^,"+V[G=8'Y$]TQ.[_=7T_(5O&AIS3=DR2J3_.K= M>!ZYX8U+P]*OV^#",<)-&=R-^/8^QKM?A(TLAU1GDD95\M0&8D#[U$Z"4>:+ MN*EBI2G[.4;,](HHHKG.T***R_$NI'2?#M]>*!^I%-*[L*344VS MRWQUKQUGQ#)'&^;6T)BC`/!/\3?B>/H*P8S@BJJGU.3ZU,C5Z$J,4D?,5IN M4#O3;)@F3V=Y-I]Y#=VS;)H7# MH?<5[_H^IQ:QI-M?0$.@;']T]Q^!R*\,TSPSK6L@-8Z=,\9Z2.-B?F<9_"O M5O`6DWVA:9-8:C-;,XD\Q(XI-Q0$<@\>H_G7%B7%K?4];`J<6TUHSJJ**SM9 MUJVT*T6YO!(8V<1CRUR??%M,Z7IS]Q M.P_-?_K5Z#7`_%H?\26Q/_3S_P"RFM:'\1'/BOX,CRNO>?""!/".EC_IW0_F M,UX-7OGA88\*Z7C_`)]8_P#T$5TXOX4<.7_&S6HHHKA/6"BBB@`HHHH`**** M`"N*\:^.TT3=8::5DOR/G<\K#]?5O;\ZO^-_%`\.:5B`@WUQE80?X?5C]/YU MXS%%/J%ZD4>Z:YN),#)R68GN?K730H\WO2V.'%XEP]R&YI:/H^H^+=7=4=I) M&.^>XE)(0>I/\A7L'A_PKIWAV`"TB#3D?/<.,NWX]A["I/#>@0>'=(CLX0#) M]Z:3'+OW/^'M6M4U:SF[+8TP^&5- M*_AQ!>(]YH:+!*5&21 M#M96&"I'8UW7@[XA2V+QV&M2-+:GY4N&Y:+_`'O5??J*V?B/X36\M7UBRCQ< MPKF=5'^L0=_J/Y?2O*J]!.->&IY$E/"U-'_P3Z15E=0RD,I&00>"*6O-OAGX MI9B-#O'S@$VK,>PZI_4?C[5Z37!4@X2LSUJ5558\R"BBBH-3ROXM+C6-/?N8 M&'Y-_P#7KBM._P"0I9_]=X__`$(5V_Q;_P"0EIO_`%Q?^8KB--_Y"EG_`-=X M_P#T(5Z5'^$CP\3_`!V?1-%%%>:>X%8?B/PI8>([8BXC$=R!^[N$'S*??U'L M:W**:;B[HF45)6D?/&J:;<:/J4UE=KMFB.#CHP[$>QKH_`/BJ31=32QN9";" MY;:03Q$YZ,/0'O\`G6[\6=,7R;+4D7#AC!(?4$97^1_.O-*]*+5:GJ>+-/#U MO=/I&EK*\,7[:GX:T^[2$;SZL.#^HK5KS6K.Q[<7S),****0S`\])3< M#RJ#[WYY`_&NQKR?XL2,?$%G&?NK;9'U+'/\A6M"*E-)G/BYN%)M&)X)T2/7 M?$D%O.NZWB4S2K_>`Z#\217N*J%4*H`4#``[5Y'\++E(?%$L3D!I[=E3W((. M/R!_*O7JTQ+?/8RP"2IW04445S':5=1T^#5+":SND#Q3*5((Z>X]Q7$_"NW: MT_MJ"3[\4ZQM]1N%>@53LM+M-.FNI;6$1O=2>;,02=S>M6IVBX]S*5.\XS[% MRBBBH-0KC?BE.8O"8C!_UMPBGZ#)_I795Q'Q60MX9MV'1;I<_P#?+5I1^-&& M)_A2/)0<5*K5#2@XKU3Y]JY:5ZG28BJ2M3P],SLUL7Q M4GJ:JRS@=ZCFN,#K75^!_`F@_(G1IS_1??OVK*I54$;T,/*I( MR?#WA;5/%,W^B)Y=JIP]S)]P>P_O'V'Z5Z-:>%O#G@RW2XNT^UWG\+S`,S'_ M`&5Z#Z_K6[JVIVOAO3$C@B16"[(($&!^78"O/+N[GOKE[BYD,DK]2?Y#T%>1 MB<9+9'JL?\`Z"*Z<7\*.++_`(F:M%%%<)ZH4444`%%%%`!2,P52 MS$``9)/:EKG?'>HG3?"-ZZ'$DH$*$>K<'],TXKF:1,YA6]RE9'CX9.K7YI>IW%%%%><>T%%%%`!1110`4444`(P#*0P! M!X(/>O!O%FC?V%XCNK1!B'/F0_[C<@?AR/PKWJO-OBW8C&G7ZCG+0L?_`!X? M^S5T8:5IV[G'CJ?-3YNQYW;7,MG=17-NQ66%PZ,.Q!R*^@M*U"/5=*MKV+[D M\8?'IGJ/P-?/%>O_``NO3<>%F@8Y-M.R#Z'##^9K?%1O%2.7+YVFX]SLZ*** MX#UCRWXM_P#(2TW_`*XO_,5Q&F_\A2S_`.N\?_H0KM_BW_R$M-_ZXO\`S%<1 MIW_(4L_^N\?_`*$*]*C_``D>)B?X[^1]$T445YI[84444`<=\4-O_"(G/7[1 M'CZ\_P#UZ\>KT7XKZNLDMII4;9,?[^7'8D84?ED_E7`6EI-?7D-K;KNFF<(@ M]S7HX=6IZGBXQ\U:R/:?A^K)X)T[=W5R/IO:NCJKIMDFFZ9;6<7W((UC!]<# MK5JN"3O)L]>G'EBHA1114EF'XS_Y$[5/^N#5X37NWC/_`)$_5/\`K@U>$UW8 M3X6>3F'QKT/4OA)_R"M1_P"NZ_\`H(KT"O/_`(2?\@K4?^NZ_P#H(KT"N:O_ M`!&=V%_@Q"BBBLCH"BBB@`HHHH`^?O$/_(R:G_U]2?\`H1KU/X9?\B=%_P!= MI/YUY9XA_P"1DU/_`*^I/_0C7JGPS_Y$V'_KK)_Z%7=B/X2/)P?\=_,ZVBBB MN$]8*\T^+5@V_3]0493#0.?0_>7_`-FKTNL_7-(AUW2)["XX65?E;NC#H?P- M:4I\DDS&O3]I3<3P.SNYK"\ANK5RDT+!T;T(KW#PMXHM?$U@)(R([E`/.@)Y M4^H]0?6O$]2TVYTG4)K*\C*31'!'8CL1[&FV%_1W5E,T,\9^5E_D?4>U M=U6DJJNCR:%>5"5GL?15%A1EH0)A_P$Y/Z9KI*9-$D\+Q2 M#Y\X45=UG2Y-&U>YL)0_M7N+M!I]F6(6*"!.@&`J@=`*S_"^@Q>' M-!M["/!=1NF=.T6%'7$LG[QQZ$]OP&*VP\;SOV-L/&\[]C6)`!).` M.YKR+5+W^V?$-S=@YC9]L?\`NC@?X_C7;>.=<_L[2OL<+8N;L%1CJJ?Q'^E< M1I=OC!Q6M>5WRE8J?-)4UT-BUBVQ@5;6/-1Q#``JX@&*S2'%%9H\5!(E7I`* MJR4F@:.C\,ZD;B`VDK9DA'RD]U_^M6[7GME=FQU"&X!X5OF]U/6O0000".AK MJHRYHV.FC+F5A:***U-0HHHH`*X+XM?\@2Q_Z^?_`&4UWM<%\6O^0)8_]?/_ M`+*:UH_Q$<^*_@R/*J]]\+?\BMI?_7K'_P"@BO`J]]\+?\BMI?\`UZQ_^@BN MG%_"CBR_XF:M%%%<)ZH4444`%%%%`!7`_%J8KHUA"#P]P6/X*?\`&N^KS_XM MQDZ5I\G99V4_BO\`]:M:'\1'/BOX,CRVO9?AF`/!L&.\LF?^^J\:KU[X63B3 MPJ\>>8KEP1]0#_6NO%?`>=@'^]^1VE%%%>>>R%%%%`!1110`4444`%AXS7IOPB8_9- M47L)(S^A_P`*\RKU'X20E=+U&8CAYU4'Z+_]>N[$_P`-GE8+^,CT&BBBO-/; M/+?BW_R$M-_ZXO\`S%<1IO\`R%+/_KO'_P"A"NW^+?\`R$M-_P"N+_S%<`C, MCJR$AE(((Z@UZ='^$CP\4[5VSZ0I:\=L_B1XBM%"S+%<@<9EA(/YC%7U^+.H M@?/I=N3[,PKC>'F>BL;2>YZG6)XG\3VOAK3S+*0]PX(AASRY_H!W->?W?Q5U M>9"MM;6ML3_%@N1^?'Z5S5LS>(-=C&K:B8VG;:US*-VWT'L/T%7##/>>QG4Q ML7[M/#]+\.J'MHS+@^E;U*K7YERQV'A\)R/GGJPHHHKF.X M****`,/QG_R)^J?]<&KPFO=O&?\`R)^J?]<&KPFN["?"SRAZE\)/^05 MJ/\`UW7_`-!%>@5Y_P#"3_D%:C_UW7_T$5Z!7-7_`(C.["_P8A11161T!111 M0`4444`?/WB'_D9-3_Z^I/\`T(UZI\,_^1-A_P"NLG_H5>5^(?\`D9-3_P"O MJ3_T(UZI\,_^1-A_ZZR?^A5W8C^$CR<'_'?S.MHHHKA/6"BBB@#G_%?A.U\3 M68#$17<8/DS@=/8^HKQG5-)O-&O6M+^$Q2KT]&'J#W%?0U9VLZ'8Z]9&VU"$ M.O56'#(?53VK>C7<-'L&Y#*SP3QW,"30NK MQ2*&5E.00>AKSZM)TW8]BA7C6C=;DE%%%9FX4444`<+\2?##:E9+JMG&6N;9 M<2JHY>/K^8_EFO)Z^D:\O\<>`7MY)=3T:(M`V6FMT'*'NRCT]NW\NS#UK>Y( M\W&89O\`>0^9Y]11UHKM/+(Y6P*ZCX6Z0-2\6BYD7,5BAEY_OGA?ZG\*Y.'[R\(^:XN-N?90/ZDURUY61W8.%YH]!KSOQE.9O$$B9XA14'\S_. MO1:\O\1DGQ%?9_YZ?T%>1B7[IWXI^X9M%%:>B:%<:W/\@,=LI^>8C]!ZFN*, M7)V1PQBY.R+7A713J=^+B9?]%MVR<]';L/ZFNWU?5K;1=/DN[IL*O"J.KMV` M]ZJ7^IZ9X3TI%9:KK%YXCO\`S[H[8UXBA4_+&/ZGU-=B M:HQMU.F=6.'CRQUDPN+RXUO4Y+VZ^_(>%'1%[*/I6M:H(U%4;6(1@5>1JYKW M=SGIJVKW+T;5.LG%44>I!)5)FZ99:3-02-33)43O0V#8R0YS7?Z+.;G1[60] M3&`?PX_I7GCM7<^%B3H$&?5O_0C6M!^\:4'[S-BBBBNLZPHHHH`*X+XM?\@2 MQ_Z^?_937>UP7Q:_Y`EC_P!?/_LIK6A_$1SXK^#(\JKWWPM_R*VE_P#7K'_Z M"*\"KWOPH=WA32S_`-.L?_H-=.+^%'%E_P`3->BBBN$]4****`"BBB@`KE?B M/8F\\'W#*,M;NLP^@.#^A-=545S;QW=K+;S#='*A1AZ@C!JHRY9)D5(\\7'N M?.5>A?"74`E[?V#''FHLR#W'!_F/RKB-5TZ72-4N;&<'?`Y7/J.Q_$8-2Z#J MK:)K=K?KDB)_G`_B0\,/R->E4CSP:1X=&?LJJ;/H*BHX)H[B".:%@\6>^%%%%`!1110`4444`%<-\5[D1^'K:WS\TUP#^"@G^HKN:\C^*.J M"[\0164;92SCPW^^W)_3;6U"-ZB.;%SY:3\SB:]M^'^GG3_!]H'&'GS.P/\` MM'C],5Y)X>T=]=UNVL4!VR-F1A_"@^\?R_F*]^CC6*-8XU"HH"J!V`K?%3T4 M3DR^GJYCJ***XCU#RWXM_P#(2TW_`*XO_,5Q&G?\A2S_`.N\?_H0KM_BW_R$ MM-_ZXO\`S%<1IO\`R%+/_KO'_P"A"O2H_P`)'B8G^._D?1&`>PI"BGJJ_E3J M*\T]LY+QOX/CUZQ-Q9QJNH0#*8&/-7^Z?Z5XVRE&9'4JRG#*PP0>X-?2-><_ M$;P?YH?6M.C^=1FZC4?>']\>_K^==>'K6]V1Y^,PW,O:1W%^'GC/SQ'HVIR_ MO0-MM*Q^^/[A/KZ>O2O1:^;@Q4AE)!!R"#R#7KW@/QD-;MQ87[@:A$O#'_EL MH[_4=_SHQ%&WO1%@\3S?NY[G9T445R'HA1110!C>+T,GA'5%'7[,Y_(9KP:O MHG4;;[9IMU;8_P!="\?Y@BOG;:5^5A@C@BN["/1H\K,5[T6>H?"-P=/U).XF M0_FO_P!:O0J\M^$MV$U+4+4G_61+(!_NG!_]"KU*N?$*U1G9@W>B@HHHK$Z0 MHHHH`***ANIUM;6:=_NQ(SGZ`9H`\`UJ3S==U!QT:YD/_CQKU[X=Q>5X*LL_ MQEV_-S7BLDAD=Y&ZN2Q^IYKW[PY9G3_#FGVQ&&C@0,/?&3^IKNQ+M!(\K`J] M24C3HHHKA/5"BBB@`HHHH`9)$DT;1RHKHPPRL,@CT(KRKQMX".E+)J.DH6LQ MS+#U,/N/5?Y?3IZQ2,H92K`$$8(/>M*=1P=T8UJ,:L;,^;J],^%>O-(D^CSM MGRQYL&3T7/S+^9!_$UR?C;0ET#Q%+#`NVVF'G0C^Z#U7\"#^&*/`D[6_C/3B MO\;M&?H5-=U2U2G<\FBY4:Z3[V/%><--S MEJX2G4UV9\QSG#$'@CM7N'PQC$?@2R(_C:1C_P!]G_"M^\T33=1R;W3[6I^@IFI^/XH(?LN@6P"J-JRR+A5'^ MRO\`C7)-;M+(7E=G<]68DG\ZD2!5[5R^U45:"L<'M96M!6_,@E^T7]RUQ>2O M-,W5W.3_`/J]JL1Q!*D``HK%MLS44M25&J=7JH#BGJ]"9HF75>G>950/3O,J MKEE<*/Q MKU:*-8HDC085%"@>PKHPRNVSHPRNVQ]%%%=9V!1110`5P'Q;/_$HT\>MP?\` MT$UW]>=?%V0"TTN//)DD;'T`']:UH?Q$<^*_@R/,J]W\&/O\'Z6?^F"C\N*\ M(KV;X;7JW7@^",,"]L[Q,/3G(_0BNK%+W4<&7NU1KR.LHHHK@/7"BBB@`HHH MH`0D*"20`.234%E?6VHVJW-G,DT+YVNAR#@X-8GCC7(]%\.7'S`7%RIAA7N2 M1@G\!S^5'@"W^S^"M/'0NK/^;$_RJ^3W.8R]I^\Y%V,3XE^&&OK8:O9H3/;K MB=5'+1^OU'\OI7E=?2)&1@\BO*_&_@*2QDDU+1XB]JY(XL9AFW[2'S+7PV\6K&%T2^DP,_P"BNQ_\<_P_+TKTNOFT'&"#@CD$ M5Z3X2^)"A$LM?<@CY4N_7V?_`!_/UHKT'?FB&$Q2MR3/2:*9'*DT:R1.KHPR MK*<@CV-/KC/2"BBB@`HHK+USQ#I_A^U,U_,%8CY(EY=S[#^O2FDV[(3DHJ[# MQ#KD'A_2);V<@E1MC3/+N>@_SVKP:YN)KV[EN)V+S3.78^K$UJ^(O$5[XJU- M9)%8(#MM[=,G;G^;'UKNO!'@'^SFCU+6$!NA\T,!Y$7N?]K^7UZ=L$J$;RW/ M+J.6+JY_^M77445QRDY.[/2IP4(J, M0HHHJ2SRSXMG_B:ZQ.-0M3Z3)_P"A"NS^+$@;Q!9Q@\I;9/XL M?\*X>)_+FC?^ZP/Y&O3H_P`-'AXE_OV?2%%-5@Z*PZ$9%.KS#W`I"`1@C(I: M*`/(/'W@[^Q;DZA8)_H$S?,H'^I8]O\`=/;TZ>E&K_*!I+"4_N9#V_V6]Q^M=U" MMS+EEN>3B\-R/VD-CTGP;XOB\26?ES%8]0A'[V,='']Y?;^5=/7SI9WD^GW< M5U:2M%/$=RNO;_ZWM7LWA'QC;>)+81N5AU!!^\AS][_:7U'\JRKT.7WH['3A M<4JBY9;_`)G2T445S':%>%^-=).C^*+N(+B*9O/B]-K<_H5^%=7&A^([2\D>`?'$:PQ:1JT MH0IA;>=SP1V1CV]C^%=&)IN7O(Y,%74'[.1Z1124M<)ZH4444`%BV+75_,L<:]!_$Q]`.YKQ/Q%KMUXIUHS MF-L$^7;P+R5&>![D]ZWH4W*5WLCDQ=90ARK=AX4TAM;\1VEKMS$&\R7V1>3^ M?`_&O>:Y;P+X5_X1W33+=`?;[D`R=]@[*/Z^_P!*ZJBO4YY:;(>$HNE#7=A1 M116!U!7->"==N=>L;Z:[=&:*[>-`JXPF`0/UKH9VV6\C?W5)_2O)OAIXACTW M59K*Z<)%>X*,>@D'0?B#CZ@5K"'-"3.>K5Y*D$]G<]=HI*6LCH"BBFNZQHSN MP55&2Q.`!ZT`>9_%T)]KTL\;]DF?IE:Y_P"']HUWXRLB!\L.Z5CZ``C^9%1^ M-M?7Q!X@DF@.;6%?*A/]X#JWXG],5W7PT\.OIFFOJ-TA6XO`-BDWE;=#^]D_H/>FDY.R'%.3LC9\$Z26D?4I5^492'/<] MS_3\Z[2HX(8[>%(H5"1H`JJ.PJ2O2IPY(V/4IPY(V"BBBK+"BBB@#(U3Q3H^ MC3^1J%]'#-M#>602V#TX`KRGQUXF@\1ZO&]H6^RVZ;$+#!8DY)QV[?E7LL]A M:73A[BU@E8#`,D88X_&F+I=@GW;*V'TB7_"MJ=2,'>VIS5Z4ZJY;V1\[[AZB MM#1]?O\`0;@S:=?]`VV_[^G_``KT@Z58'K8V MI^L2_P"%-.C::>NGVA_[8K_A6?M*7\IM[&NOM_@><'XN7W;3;;_OXU,;XM:F M?NV%F/J6/]:](.A:4>NF67_?A/\`"FGP]HYZZ78_]^%_PH]I2_E#V-?^<\RD M^*NMO]R&Q3Z(Q_\`9JH7'Q$\17`(^W+$#_SRB4?K@UZT?#6BGKI-C_WX7_"D M_P"$9T3_`*!-C_WX7_"J56DOLD/#UW]L\*GNKW5KM3//-=7,A"+O8L23T`KW M_3+0:?IEK:+T@B6/CV&*CMM%TVRD$EK86L+CHR1*"/QQ5ZLZU7GLDK&N'P[I M7Q]Q7G.K>#]:T8L;FR=XA_ MRUA^=/TY'XBO=Z*WAB)0TW.6K@Z=379GS_I'B/4]#?\`XE]X\:YR8C\R'ZJ> M*[&Q^+5PBA=0TZ.0_P!^%]OZ'/\`.N^O=`TK46MZA]`JG_V:H[CXLZ:@ M_P!'L;N4_P"UM0?S-7Q\,O#V?]5<'V\\U:@^'_ARWP?[.60_]-)&;^9J+T>S M-.7%=TNVSM((!_TSC"_RJU1[=1^!6#ZJYN]65SG_``[X-TSPX`\" M&:ZQ@W$O+?A_='TKH***PA:7<2P7>H(L\1P M\:JS,#Z<"MVJLNFV4\ADFL[>1SU9XE)/XXIQMU)ES6]T\.\5:XOB#Q!/>Q@K M"<)$K==HZ9^O)_&L?*GN*^B5TRQ3[ME;#Z1+_A3FT^T;[UK`?K&*ZUB5%62/ M/E@)2;DY'%^'?B5I1TNW@U25K>YB0(S;"RO@8R",UT^F>)M(UF=H=.OHIY57 M>47(..F>1[U9.D:>>MA:G_MBO^%2P6-K:L6M[:&%CP3'&%)_*N>3@]4CLA&I M&RDTR>BBBLS8*K7]A;:E9R6MY$LL$@PRM_G@U9HH!J^C/'O$?PYU#2Y7FTU' MO;/J`HS(@]"._P!1^5>,Y4\JRG^=?1U136L%Q_KH8Y/]]0?Y MUU1Q32M)7."I@(MW@['F6A?%6:W18=:@^T*.//BP'_%>A_#%=7;_`!$\-W"@ MG4!$?[LL;`_RQ6W_`&/IW_0/M/\`ORO^%']CZ=_T#[3_`+\K_A6!B0'3ID=:LTR*&.",1PQK&@Z*@P!^%/K$W5[:G M*^*_`MGXBSM>6ZQX7U;0V87MF_ECI*@W1G\1T_'%>^ M4A&1@\@UO3KRAINCFK82%5WV9XGH/C[5]$C6$2+=VR\".8D[1[-U'ZUUUM\6 MK!@/M6G7,;=_+97'ZXKJ+WPIHFH,6N=,MF8]65-I_,8K+D^&OAUSD6TR>RSM M_4U;J49:M&4:.(IZ1DFBF_Q6T8*2MM?,?38H_P#9JQ=2^+-Q(A73;%(<_P#+ M2=MQ'X#`_6NEC^&GAU#DV\S^S3M_2M2R\)Z'I[!K;3+=7'1F7>?S.:GFHK9- ME\F)EHY)'E%OI'B/QI>"XD6:8'_EO/\`+&H]O\`*](\+^!['PX!.Q^TWQ',S M#`3V4=OKUKI@,#`Z"EJ9UI25EHBZ6%C!\SU84445B=(4444`1SH9;>1%ZLI4 M?B*^>;_3KO2[@V]];R02+QAUQGZ'N/I7T545Q;07<1CN88YHSU610P_(UM1K M>SZ'-B,/[9+6UCR'0OB/JFD1)!=*M];KP/,;#J/0-W_&NJM_BOI+K^_M;R)O M0*K#\\UKW/@+P[=$EM-CC)[Q,R?H#BJ9^&7AXG_4W`]O/:K+Y/L5O"R0N?^/:V!8O_`+QZG]!7 MHEO\/?#EN<_V>)#_`--9&;],XK=M+&UL(O+L[>&!/[L:!1^E)5*<-8HIT:]3 M2N@HJ91 M4E9DRBI*S/);VQN=/G,5W"T;]L]#]#WJ"O7+BVANHC'<1)(AZJXR*P+OP1I\ MY+6[RVY/93N7\C_C7)+#-?"<<\*U\)P5%=5+X"N0?W5Y"P_VD(_QJ,>!+XGY MKJV`]MQ_I6?L9]C+V%3LNP[K&@7]3FMW3]!T_3<-;6 MZ^8/^6C?,WYFKCAYO?0N.&F]]#D-&\(W-\5EO0UO;]<'[[?AV_&NZM;6&RMT M@MXQ'&@X45-1753IQAL=E.E&GL%%%%:&@4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%% M%%`!16/XFUJ?0=)>]@L6NPGWP'"A!_>/?'TIOA+5Y]=\/PW]TL:22L_RQ@X` M#$#K]*KE?+S=".=O,_&=I=MXXT>W?4[DK<2!HR,#[.2^/E`'7W/-=II6A7 M.G79FFUJ_O5*E?*G*E?KP.M:2@E%.^YC"JY2<;;">,?^10U7_KW:J7PZ_P"1 M)LOK)_Z&U7?&'_(H:K_U[M_*N9\&:)=ZOX2MO/U6ZMK0%Q'#:$1D_,=:;<:EX7\>P:+/?SWMC=+E/.;<1D'!]B",>A MKT6HG#E-:=3G3TLT%%<3KOB=)O$3:.-0>PM+==US<1*6D=NR*0#MZ\FLC6]6 MM-)2&[\,:GJ$UTL@\R"4RR1R+WSO'\O6J5)LB6(BK^1Z;14%E<&[L8+@H4,L M:OL/5.9TD@A<8CC.['('WL8SS4PAS.Q=2IR1YK7 M/2**Y;3?#.L6?B8:A=:]+=VQ0AHF!7<2.FW.T`=>*T?$NIWNEZ7OTRQDO+N1 MA'&BJ2%)_B;';BDXZV3!3?*W)6-BBN(U_P`/WJ^')=2DUG41J4$/G-MFVQY` MR5"K@`=I`1^&+R>PO'M984,A9`"6`ZKGM]17.>#-(O=9\*1--J]W;VYDDVI;$*[' M<'/1 M@.01UKTR.198ED0Y5P&!]0:4XM4J M39$L1%7\CTZBH;6?[3:0S["GF(K[3U7(S@UP8FOK7XJ6VGOJ5W/:E3*LZFDFE>63<\C%B?F/T]_DL=/4%K>V][YWV:59/)D,4FW M^%QU'ZU1\1PW$NB7)M;V6T>.-I-\0&3A2<9(X^HYKB/`.AW6I^'WN(M:O[,& MX8&.!AM)P.>0>33C!.+DV3.HU-12/3*SI=`TR?5DU.6SC:]CQME.&,#KTZF ME"+;=F.K-12;5]3T2BDKE=3UB\U3Q+_PC^CS?9_*3S+R["AF01S[^ MU*,6RY343JZ*Y74?!;RVS/I^L:I#?*,I+)=.P8_[0_PKH;".XAT^WCO)!+<) M&JRN.C-CD_G0TK:,492;LT6:*X2*_P#^$A\H7L]O;6OR6]M%*8O-(ZD MD8)/?%;^AZ3>Z1J5Y&UW-@5SWBKPA#XF^SR_ M:7M;FWSLE09XZX(^HJWH^D7MBWF:AJ]Q?R;=BAE"(H]<#J?[52^'7_(DV7UD_P#0VK0U[1)M/5)];NS>Q8\MQ$@"`=`!C'-KHZR-UEC5XV#(PRK*<@CU% M'?^`?^AFN_1%C1410JJ,``8`%34M6CU*XUJZ^U0D&%E MC0",`Y``Q4TFD[LNO&4HI)'65C^)?$=MX9TS[7O8<5H64, M]O;!+JZ-U("(/[;OO"-[>7ES!90FW+_98$WLP(Z,Y_H!]:T/AVNWP38^Y<_\`C[5' M;>"Y7TPV&K:U>7ML$V)$N(U4=LXR6QQC)Q[5+X;\)W/A\B,ZQ<3VB,6CMQ&% M7)]3R3].!FM)./(XWZF$8S513:Z6W+GB_P#Y%'5?^O9_Y5G?#?\`Y$JU_P!^ M3_T,UH^+_P#D4=5_Z]G_`)5R7@+1]6;08[O3]:^S0S.VZ![<2*"#C(R>#Q1% M)TGKU";:KJROI^I8^*0-Y;Z5IT"[[JXN#L0=<8Q_-A7<6D/V:SA@SGRHU3/K M@8K,T[PY#::@VHW<\M]J++M^T38&P>B*.%%;-1*6BBNAK"#4G-]3SGPI?KI? MQ"URPO6"27";D*L6K:]?7]H/\`EV)*HX]&Y)(]JN;C/WKV9G352G>- MKKH=6CK(BNC!D895@<@CUKS^]8)\9[0L<`P@#/KL:O0%4(H50`H&``.`*YOQ M-X,BU^]@OH;N6RO80`LJ#.0#D>G(/?-33DDW$]4)(`^ MS/\`RK*^&G_(F6__`%UD_P#0C3KCP?=W^ES6^IZU'$51JEU.@);R<*L63U..OZU5XJ#CM,X[XI1:Y'%LN^AB\F!(@S MOL4+N=LL<=R>YKEKOP-)?:O'JD^MW1O(L>6ZQ(`@'0`8QW-*FTF[A7C*222Z MG6UYOH-\FD_%#6+:^;8;QR(V;@9)W*/Q!KT.VCDBMXTFF,TBKAI"H7)MDLQ>"Z0;5GCQG'H1W%%.25U+9CK0E*TH[HZ"H[>XANX5FMY$EB M;.'0Y!P<'GZBN4M/`]ZJ""_\2:A_T;5R9+FP(`D)R2,D$$]^G!]ZNVOA:^TFXN3H^LF"VN)#(8)K<2A& M/4J'H-#^T2B62XN[I]\]Q)CYGGNH62-886?GIR0,#KWK-^'UV]GHUOI5Y9WMO M GRAPHIC 20 image_006.jpg GRAPHIC begin 644 image_006.jpg M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX. M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_ MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T] M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`!*`0X#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`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`DF4D^PKRV&X*'BO8_'FE/JWA>=(Q MF2(B50.IQVKQ,=,'J*[<*_^(]0^SV2CCF2 M5ONQCZUCJLLTL<$()DE8(H]2:]6N+*/PCX3@L+;BXN/];(/O$XY_PIXBNJ4; MF.'H.I=R>B.=.EZ1I+&*&,7URO#S3?VT:`Y8@&7'8"O&5>?+7Z5Y9\0O^1WLOHG\Z]4C M_P!6OTK>I_#B\;Q)X\M='R?LEO*%=<]3W->FQ0 MK#&D:`!$&`!VKR+2)/(^*$GG'YFN&7GU->P5O67*DEV.3#/FE.3WN`%(0>32 MGBC-8'7L>8?%#2!:7=KJUL-CNVU]O'S#D-7;>$]4;6/#EK=.\P;:D^&D;)X3C9N`[DK]*W?O4M>AQIC6G%G#_`+@_E7G'Q4)&M:85&65,@>OS5T=MXEU".Q0R:%<_(@Z.#D8I-7IH M:FE7EDKU@_=/TKR?PA_R4R\_WI**6S#$;Q]3UBEI,TM8'4<#\5_\`D%67_7;_ M``KM[7BR@_ZYK_*N(^*__(*LO^NW^%=Q:_\`'G!_US7^5:OX%\S&/\67R.1^ M)VFS7V@17$"LQM7WLJ]<'O\`A4G@SQG;:Q9Q6ERZQ7D:A=IX#X[BNMD19$*. M`RL,$'H:\U\5_#V2VE;4=`!&/F:!3R#ZK_A3@XR7(S.M&<9^T@>E''2EW#'% M>?>!_&\EW.NE:LQ\\<1RL,;L=C[UZ"*F<'!V9K3JQJ*Z`C(PPR#P:\U\7_#N M5[F6^T5`VX[G@Z<]R/\`"O3,4`8HA-P=T.I2C45F>(^$-(N/^$WLXKVUECV$ MO\ZDJQ_P"K7Z5YGXJ\+^(?$&O&_ALHXE4*$5I@3QWKH[2_ M\6P6Z)/H]O(RC&5G'-;RM*$5?8Y(-QJRDUHSK*9+(D49DD8(B\EB<`5S3ZMX MI_AT.+\9Q6?=GQ?K!2SN=/MK:SD8>:RR9;;Z5GR>9NZO9,Y_Q_I5/<&I[G3[>^T\VEW&LL3+M*FN'_X M0S6?#=\UUX9NEDB8\V\IQN^M:)==B41W MGAZ5I.YBD&VGS77B?55\JVM(M-B88,TK[W'T`K/D9LJJ[&%\0[I];U2Q\/V! M+S;M\NWG;]?YUW.D:>FE:7;V<8&V)`/Q[FJ&@>%K70P\H9I[R7F2XDY9C6TV M0"0N3C@9ZT2EHHHFG3?.YRW9YK\4C_Q/=)/HO_LU>BVF#90_[@_E7`^,O#VO M^(]6@N+>Q2..W7:NZ8?-SG-=CH\M^;:*&]L?LY2,`MY@8,1]*N5O9I(B-_:M MM'%^-_#D^D7R^(M$S&Z'=,J]O?Z5U/A3Q1!XDL`P(2Z0?O8\]/<>U;KQK(C) M(H96&&!Z$5Y[J'@74=)U?^TO#$RCYL^0S;<>V?2A24X\L@G"5.7/#;JCT2O) M8S_PCWQ2?S_DCFE)#'^ZU>@Z;J&LRHBZAI2Q/_$Z3J5_`56\5>$;?Q+`KA_) MO(_N2@?H?:E3:B]2JL74A[NZ.A4@X/K17%Z?>>*-!B%K?:>NH0H,1RQ.`S?6 MK;ZYX@OHMECH9MY#_P`M+B0$+[X%2X,N-5-:HRO'[?VIKNCZ/#\\ADWR`?PK MZUWJ($B5/[H`KG_#_A?^SKJ34=0G-UJ4WWI2.%]A71$8%$FK)"IIWM]5T58YECB\N2%FQN%31>)M89!&?#LXE(ZF M4;Z9%9>+=,NK-0DMQ(I95[MGK7IR;O+7=]['/UKEM/\` M#=[?ZVNL^(#'YT8Q#;IRL?XUUGTJYRNDNQ%&%IREW'4445D=`AI"*=24`8.L M^%;;4F,T)\B<]6`X/U%XC8;94'8L!S^=)Q$JB>QOTM9-R\FGV$2S M:@Q>63'F,OS'/\(%4%U.Z?PA=W8G(N(F95DX)X('-%M!\VO*=)FEZU@6T]Y! MK=K";EKF"X@:1]P&8R`,8QZTVPO;W4+KSDO(4B6U3_C63>74UOK6DVZ3'RYO-$@('S87(J)+U[[4;V`W9M3 M:R!0HQ\PQG//:E8;>ES;SFC&:PM1U"XMM4AW2LMDP5-\>#AR>C#WK<'M18%) M-V'T444B@HHHH`****`$I:**`"DI:*`"BBB@`HHHH`****`"BBB@`I*6DH`@ MELX)KA)I(P94&%;N!3&T^V=Y':(%I!M<_P!X>]6'Z4O\7X4"L5WT^UDM5MGA M5H5^ZIZ#Z4-I]LUJ+=H@8?[AZ59[T#J:`LB":R@N(5CEC#*ARN>QK/U72P^A MW=K8P@/./N@X&K` M=3Z_6K([T?Q4[A8J3Z7:7,C/-`K.Z[')_B'O3Y;"WFMT@DB#1H05'ICI5D]1 M3<\FE<+(B>T@EDCD>,%XON'N*9+IUK-<">2%3*/XL GRAPHIC 21 image_007.jpg GRAPHIC begin 644 image_007.jpg M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX. M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_ MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T] M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`!*`0X#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`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`DF4D^PKRV&X*'BO8_'FE/JWA>=(Q MF2(B50.IQVKQ,=,'J*[<*_^(]0^SV2CCF2 M5ONQCZUCJLLTL<$()DE8(H]2:]6N+*/PCX3@L+;BXN/];(/O$XY_PIXBNJ4; MF.'H.I=R>B.=.EZ1I+&*&,7URO#S3?VT:`Y8@&7'8"O&5>?+7Z5Y9\0O^1WLOHG\Z]4C M_P!6OTK>I_#B\;Q)X\M='R?LEO*%=<]3W->FQ0 MK#&D:`!$&`!VKR+2)/(^*$GG'YFN&7GU->P5O67*DEV.3#/FE.3WN`%(0>32 MGBC-8'7L>8?%#2!:7=KJUL-CNVU]O'S#D-7;>$]4;6/#EK=.\P;:D^&D;)X3C9N`[DK]*W?O4M>AQIC6G%G#_`+@_E7G'Q4)&M:85&65,@>OS5T=MXEU".Q0R:%<_(@Z.#D8I-7IH M:FE7EDKU@_=/TKR?PA_R4R\_WI**6S#$;Q]3UBEI,TM8'4<#\5_\`D%67_7;_ M``KM[7BR@_ZYK_*N(^*__(*LO^NW^%=Q:_\`'G!_US7^5:OX%\S&/\67R.1^ M)VFS7V@17$"LQM7WLJ]<'O\`A4G@SQG;:Q9Q6ERZQ7D:A=IX#X[BNMD19$*. M`RL,$'H:\U\5_#V2VE;4=`!&/F:!3R#ZK_A3@XR7(S.M&<9^T@>E''2EW#'% M>?>!_&\EW.NE:LQ\\<1RL,;L=C[UZ"*F<'!V9K3JQJ*Z`C(PPR#P:\U\7_#N M5[F6^T5`VX[G@Z<]R/\`"O3,4`8HA-P=T.I2C45F>(^$-(N/^$WLXKVUECV$ MO\ZDJQ_P"K7Z5YGXJ\+^(?$&O&_ALHXE4*$5I@3QWKH[2_ M\6P6Z)/H]O(RC&5G'-;RM*$5?8Y(-QJRDUHSK*9+(D49DD8(B\EB<`5S3ZMX MI_AT.+\9Q6?=GQ?K!2SN=/MK:SD8>:RR9;;Z5GR>9NZO9,Y_Q_I5/<&I[G3[>^T\VEW&LL3+M*FN'_X M0S6?#=\UUX9NEDB8\V\IQN^M:)==B41W MGAZ5I.YBD&VGS77B?55\JVM(M-B88,TK[W'T`K/D9LJJ[&%\0[I];U2Q\/V! M+S;M\NWG;]?YUW.D:>FE:7;V<8&V)`/Q[FJ&@>%K70P\H9I[R7F2XDY9C6TV M0"0N3C@9ZT2EHHHFG3?.YRW9YK\4C_Q/=)/HO_LU>BVF#90_[@_E7`^,O#VO M^(]6@N+>Q2..W7:NZ8?-SG-=CH\M^;:*&]L?LY2,`MY@8,1]*N5O9I(B-_:M MM'%^-_#D^D7R^(M$S&Z'=,J]O?Z5U/A3Q1!XDL`P(2Z0?O8\]/<>U;KQK(C) M(H96&&!Z$5Y[J'@74=)U?^TO#$RCYL^0S;<>V?2A24X\L@G"5.7/#;JCT2O) M8S_PCWQ2?S_DCFE)#'^ZU>@Z;J&LRHBZAI2Q/_$Z3J5_`56\5>$;?Q+`KA_) MO(_N2@?H?:E3:B]2JL74A[NZ.A4@X/K17%Z?>>*-!B%K?:>NH0H,1RQ.`S?6 MK;ZYX@OHMECH9MY#_P`M+B0$+[X%2X,N-5-:HRO'[?VIKNCZ/#\\ADWR`?PK MZUWJ($B5/[H`KG_#_A?^SKJ34=0G-UJ4WWI2.%]A71$8%$FK)"IIWM]5T58YECB\N2%FQN%31>)M89!&?#LXE(ZF M4;Z9%9>+=,NK-0DMQ(I95[MGK7IR;O+7=]['/UKEM/\` M#=[?ZVNL^(#'YT8Q#;IRL?XUUGTJYRNDNQ%&%IREW'4445D=`AI"*=24`8.L M^%;;4F,T)\B<]6`X/U%XC8;94'8L!S^=)Q$JB>QOTM9-R\FGV$2S M:@Q>63'F,OS'/\(%4%U.Z?PA=W8G(N(F95DX)X('-%M!\VO*=)FEZU@6T]Y! MK=K";EKF"X@:1]P&8R`,8QZTVPO;W4+KSDO(4B6U3_C63>74UOK6DVZ3'RYO-$@('S87(J)+U[[4;V`W9M3 M:R!0HQ\PQG//:E8;>ES;SFC&:PM1U"XMM4AW2LMDP5-\>#AR>C#WK<'M18%) M-V'T444B@HHHH`****`$I:**`"DI:*`"BBB@`HHHH`****`"BBB@`I*6DH`@ MELX)KA)I(P94&%;N!3&T^V=Y':(%I!M<_P!X>]6'Z4O\7X4"L5WT^UDM5MGA M5H5^ZIZ#Z4-I]LUJ+=H@8?[AZ59[T#J:`LB":R@N(5CEC#*ARN>QK/U72P^A MW=K8P@/./N@X&K` M=3Z_6K([T?Q4[A8J3Z7:7,C/-`K.Z[')_B'O3Y;"WFMT@DB#1H05'ICI5D]1 M3<\FE<+(B>T@EDCD>,%XON'N*9+IUK-<">2%3*/XL GRAPHIC 22 image_008.jpg GRAPHIC begin 644 image_008.jpg M_]C_X``02D9)1@`!`0$`>`!X``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX. M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_ MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T] M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"``R`/D#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V4D*"6(`' M))KD-1^(%ND[0:5$+EE.#,QQ'GV[G]*9\3M4EL/#T=O"Q4W@3^+-<"^8K6R`]A%D?SJ*T^)MQ;3A- M4LTDC[R0<,/^`G@_F*Y236MT>,U%9:1?Z\KSVZ+':(Y]AFMG2I MI7FK'(L15E)>S;9[7INIVFKV27=C,LL+]QU![@CL?:K=><>`8$T?6FM8;V6Y M2Y4[P(]D>X#((R<^H[=:Z?6?$SZ5K$5FELLRM%YC'?@KR1CI[5YLYTU=Q=T> MK"M>'-+0Z"BLS3]>M;]A'\T4QZ(_?Z'O6G0FGJC9-/5!61>^*M(TV0)?736[ M-G:)877/TR.:UZ\\^+P_XEVFGOYK_P#H-:TXJ4E%F=>;IPQ(`-6ZHZ(,:%IX'3[-'_P"@BKU0]S2+;2;"BBO/]1UBY\7^ M+#X?T^=[?3H2WVJ6(X:0+PP![#/'ZU4(.1%2HH6[LZNZ\3:3:3F![U'G'6*$ M&5Q]0H)%1-XKL8QND@U%$_O-8S8_]!J_IVF6>DVJV]A;QP1+V0=?Z.T^Z,O3_$ND:I)Y=EJ$$DG3RRVU_\`ODX-:E8/B3PC8>(K9O,C6*\`S'!?%%]#J[^'M:=I)$+)%(YRRLO52>XP#@U?(I1LG_`*":Y[X4?\BO/_U]M_Z"M"C'D&^\R"TDNV2Y)` M$+0R!R3TXVYK6BD$L:NH8!N1N4J?R/-<)K`'_"X-(X_Y=_Z25WU:3BHI6ZF5 M*QTF-7O[J.'><*&.68^RCD_A5"3Q=IT*%Y8[](A_RT:QE"_G MMKD;C54T'XI7-SKJ,89(]EO*1D1*<8(]N"#CU->BV]Q#=P)-;RI+$XRKHV01 M]:S%U83":!B0'`(Y'7K5NJMAI\&FPO%;+M1Y7 ME*]@6.3CVR:M5F[7T-E>VISWC7P\WB+06@@Q]JA;S8<\`D#E?Q!_E7B,T,MM M.\,\;Q2QG:Z.,%3[BOH^LO5_#>E:X!_:%G'(X&!(/E]87BNUGTS5#>V\,(CG(/G- M'O*OZ<\#VXKEQLW46FQG[!TJ-OO(M"6'0HFUC4R8P5*VT7\"*ZW0+]M0TM))#F1"48^I'?\`+%><_:7KEM$ M\1/;:-:6][I&K13PPK&^+-V!(&,@CZ5=;Q7;K_S#M7/TL)/\*EPE>XMB MD<:9^8\^V:K^+?`Z:Y<+J&GS"UU),'?R%*U%\7Z8X^5;XM_<^Q39_]!K- MTY(W56#W=O4W*\HM8#J7Q@E:U&4AN3([#H`JX/\`X]Q^-=E>:GK>K1-;Z+IT MMFK\&\O1LV#U5.6)^N*M>&?"]IX:M&2%FFN9>9KA_O.?Z#VJX/V:=]V95(^U ME%+9:DOBK_D5-5_Z]9/_`$$UQWPW75_[`F.GR6(@^T-E9T.H&!^-8'PY,^CZ3<6>I6=Y;R-/O3?;OA@0!U M`]J<=*3)J:UX^A3\7ZKK%M=0V6O#R-&G.V2;3PF66 MD0KHHC^R.-RNASO/J3W-6[VRM]1M)+6\B66"089&'6N#30]?\$:B\NAH^I:5 M(V6MB?F'X>ON/Q%":G'EV?YC:E2GS/5?BO\`@'HE>6>'_D^+]Z&X+2W&/Y_R MKO;#Q!%>1J9;/4+20\&.>U<8/U`(_6N>\4>$;XZY%X@\/LGVV,AI(6.`Y`QD M'W'!%*G[MXRTNAUES*,XZV9V]%,4$875M,U&PG'W@;9Y$S[,H.14TGBI M)5VZ9INHWTI^Z!;M$F?=W``J.278U]K#N8&ICS?C#I83DQVV6]N)/\:[VN:\ M.^';J#5;K7-9>-]2NAM"1\I`G]T'N>!S[5TM.HT[)=$31BU=OJ[F?K&AV&O6 MGV?4(!(HY5APR'U![5Y_?^'==\",^H:'>/<6"G=)&PS@?[2]"/<8/TKHM'\4 MSV4!M-?L=1AGC=@)_L[R)(NXX.5![5:U'Q$;ZREM]'TZ\O)YD**6@:*)7(K;)8\YVL/3VY!K9K`\&^ M'#X9T06TKB2XD?S)67H#@#`]@!6_64[GSDAR1].PK5HHK11459&D8J*L@HHHI MC"BBB@`HHHH`****`"BBB@".>XBM8'FN)$BB099W.`!]:HZCJZVD-G-"8I8I M[E(6??PH;/.?;%3ZK8#5-*NK(OY?GQM'OQG;D=<57O=-FOH+-9)8E>WG2=BL M9PQ7L!GBJ5NI$N;H7H;F&XB\R&6.2,$C5"^O/W0?Q-2V^F21VMPDGV0331^69(H-F1@@9 MY.>O3-%EW"\NQLF\;1^/ M2J*:1+#H-O80S1+)`L:B4P@AMF.QZ$@=>W:L[4M(FLO">L6RL;E[@RR(J1DL M6><],>GXU'H^BG2UB1VMY1`GEQRB#;(5 M]SGV&<`9ZTK(:6[B,K<1,)21'AP=Y'4#UZ&D%[;&Z:U%Q$;A0"8]XW M`'../P-9$'AZ>#[$BW41BL[J2X0&([F#[\J3GMO//M5Z+3G@UNYOEE0QW,:* MZ%.04W8(.>^[T[4-+N"YVB^F:8/&F"A..,$\CC\>:LO8W%SI\UO>/:R& M5-A`A(0COD;L\_7BBR!.78O131SINAD5USC*G/-/JGIEG)8VIBEN'G.\LI?D MJ#T7)Y./4\U